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Abstract 36 
 The role of adaptive immunity in early cancer development is controversial. We show 37 
that chronic inflammation and fibrosis in humans and mice with non-alcoholic fatty liver disease 38 
is accompanied by accumulation of liver resident immunoglobulin A (IgA)-producing cells. These 39 
cells also express PD (programmed death) ligand 1 (PD-L1) and IL-10 and directly suppress 40 
liver cytotoxic CD8+ T cells (CTL), that prevent emergence of hepatocellular carcinoma (HCC) 41 
and express a limited repertoire of T cell receptors against tumor-associated antigens. Whereas 42 
CD8+ T cell ablation accelerates HCC, genetic or pharmacological interference with IgA+ cell 43 
generation attenuates liver carcinogenesis and induces CTL-mediated regression of established 44 
HCC. These findings establish the importance of inflammation-induced suppression of CTL 45 
activation as a tumor promoting mechanism. 46 
 47 
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The successes of immune checkpoint inhibitors1 and adoptive T cell transfer2 in cancer 60 
therapy demonstrate how activated immune cells eradicate established malignancies. However, 61 
the role of adaptive immunity in tumorigenesis and existence of immunosurveillance remain 62 
controversial3,4. We investigated how adaptive immunity affects hepatocellular carcinoma 63 
(HCC), a leading cause of cancer deaths. Other than surgical resection or ablation of localized 64 
tumors, no effective HCC treatments exist. HCC is initiated by chronic liver inflammation driven 65 
by hepatitis virus B or C (HBV, HCV) infections, alcohol consumption or non-alcoholic fatty liver 66 
disease (NAFLD)5. Liver fibrosis is another outcome of chronic hepatitis, but its exact pro-67 
tumorigenic function remains obscure6. The contribution of adaptive immunity to HCC 68 
development has also been elusive. T cells activated by viral antigens or during non-alcoholic 69 
steatohepatitis (NASH) were suggested to promote HCC by inducing liver damage7,8, whereas 70 
alcoholic steatohepatitis (ASH) causes immune dysfunction9, and T cell produced interferon γ 71 
(IFNγ) attenuates liver fibrosis10. Moreover, a key mediator of liver fibrosis which usually 72 
precedes HCC development, TGF-β, is a potent immunosuppressive cytokine that inhibits anti-73 
cancer immunity11. TGF-β stimulates class switch recombination (CSR) that converts IgM-74 
expressing B cells to IgA-expressing cells with regulatory activity12. ASH or NASH patients with 75 
liver fibrosis exhibit more circulating IgA than non-fibrotic patients13 and IgA+ cells interfere with 76 
activation of cytotoxic CD8+ T lymphocytes (CTL)14. We now show that IgA+ cells, found in 77 
human and mouse NASH-afflicted livers, mediate immunosuppression that fosters HCC 78 
development by inhibiting a strongly protective, tumor-directed CTL response. Manipulations 79 
that unleash CTL activity cause regression of established HCC in mice and should be applicable 80 
to humans. 81 
 82 
 83 
 84 
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IgA+ cells accumulate in fibrotic liver  85 
Serum IgA was elevated in two cohorts totaling 598 NASH patients (Extended Data Fig. 86 
1a,b), paralleling liver-intrinsic cell-bound and interstitial IgA, which correlated with fibrosis 87 
scores (Fig. 1a,b; Extended Data Fig. 1c). CD8+ T cells were also elevated in fibrotic livers (Fig. 88 
1c; Extended Data Fig. 1d). Mouse models of NASH-driven HCC (Extended Data Fig. 2a), 89 
including high fat diet (HFD)-fed MUP-uPA mice, which show classical NASH signs including 90 
fibrosis15, and mildly fibrogenic HFD-fed streptozotocin-treated mice (STAM)16 (Extended Data 91 
Fig. 2b,c), exhibited elevated serum IgA before and after HCC development (Fig. 1d). MUP-uPA 92 
mice, which show some fibrosis on normal chow (NC), exhibited elevated serum IgA before 93 
HFD feeding that was abrogated by NASH-preventive TNFR1 ablation15. However, 94 
diethylnitrosamine (DEN)-induced HCC or HFD feeding of WT mice, neither of which are 95 
fibrogenic17, didn’t elevate IgA (Fig. 1d). IgA in mouse serum correlated with liver IgA+ 96 
lymphocyte content, which was particularly high in HFD-fed MUP-uPA mice (Fig. 1e,f). Mouse 97 
and human NASH-induced HCC also contained IgA+ and CD8+ T cells (Fig. 1g,h). IgA staining 98 
was diffuse early and became more defined and perisinusoidal at higher NASH grades, 99 
whereas human and mouse HCCs contained IgA+ cells with plasma cell morphology (Fig. 100 
1a,g,h). Spleen IgA+ cells were also elevated (Extended Data Fig. 2d). HFD feeding of WT and 101 
MUP-uPA mice caused weight gain and mild liver damage, but MCD-fed mice exhibited severe 102 
weight loss and extensive liver damage and STAM mice didn’t gain weight (Extended Data Fig. 103 
2e-h).  104 
 CSR to IgA is stimulated by TGF-β1, LPS, IL-33, IL-21, CD40 and lymphotoxin18,19. 105 
NASH and fibrosis correlated with elevated liver TGF-β1, although it was also elevated in non-106 
fibrotic HFD-fed WT mice (Extended Data Fig. 2i). In MUP-uPA mice, TGF-β1 was mainly 107 
expressed by CD11b+ Kupffer cells (KC) (Extended Data Fig. 2j). HFD induced IL-21 in liver 108 
CD4+ T cells with follicular helper (Tfh) markers only in MUP-uPA but not BL6 mice, as well as 109 
IL-33, chemokines and receptors that control B and T cell recruitment and IgA CSR (Extended 110 
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Data Fig. 2k-o). Thus, NASH-bearing MUP-uPA livers contain factors and cell types needed for 111 
generation of IgA+ cells. Flow cytometry revealed that MUP-uPA spleens contained two main 112 
IgA+ cell populations: IgA+B220+CD138low/-, which are probably germinal center or memory B 113 
cells but not antibody-secreting cells, and IgA+B220-CD138+, corresponding to plasmablasts or 114 
plasma cells (PC) (Extended Data Fig. 3a-f). MHCII staining revealed two further 115 
subpopulations, MHCIIhi cells that are probably plasmablasts and MHCIIlow PC (Extended Data 116 
Fig. 3g,h). The liver harbored both populations, with 5% of cells being IgA+B220+CD138low/- B 117 
cells and around 95% being plasmablasts/PC (Extended Data Fig. 3a-f). Most IgA+ cells were 118 
CD11b and CD5 negative (Extended Data Fig. 3i,j) and expressed high levels of PD-L1 and IL-119 
10 (Fig. 2a-c). CD19+IgA- cells, however, hardly expressed PD-L1 or IL-10, and PD-L1 in 120 
CD138+ plasmablasts/PC was higher in IgA+ cells than in IgA- cells (Fig. 2b and Extended Data 121 
Fig. 3e; 4a-e). HFD feeding increased liver IgA+ plasmocytes as early as 3 months of age, with 122 
a minor effect on intestinal IgA+ cells, which barely expressed PD-L1 (Extended Data Fig. 4f,g). 123 
Most liver IgA+ cells in human NASH expressed PD-L1, whereas 10-15% of CD8+ cells were 124 
PD-1+ (Extended Data Fig. 1c,d). 125 
To investigate how IgA+ plasmocytes affect NASH or HCC, we generated MUP-uPA/Iga-126 
/- and STAM/Iga-/- mice (Extended Data Fig. 2a). IgA deficiency abolished IgA+PD-L1+IL-10+ cells 127 
and had no effect on other PD-L1- and/or IL-10-expressing CD45+ cells and chemokine 128 
expression (Extended Data Fig. 2n and 4b,h). IgA ablation barely affected weight gain, liver 129 
damage or glucose tolerance and didn’t alter serum and liver lipids, lipogenic and PPAR target 130 
genes (elevated in NASH), liver histology, fibrosis or steatosis in either MUP-uPA or MCD-fed 131 
mice (Extended Data Fig. 5a-j). MUP-uPA/Cd8a-/- and STAM/Cd8a-/- mice were generated and 132 
showed no alterations in weight gain, glucose tolerance, ALT release, serum triglycerides, 133 
lipogenic and PPAR target genes or hepatocyte ballooning, although steatosis, liver triglycerides 134 
and serum cholesterol were reduced (Extended Data Fig. 5a-e,g,j,6i), probably due to early 135 
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HCC development. Consistent with the anti-fibrogenic effect of IFNγ10, CD8+ cell ablation 136 
enhanced liver fibrosis in MUP-uPA and MCD-fed mice but not in CCl4-treated animals, whose 137 
collagen deposition pattern was different (Extended Data Fig. 5g-i). Induction of alpha 138 
fetoprotein (AFP) and other regeneration antigens in MCD-HFD and CCl4-treated livers can 139 
explain the origin of HCC-independent, damage-related CD8+ T cell activation (Extended Data 140 
Fig. 5k). Unlike CDD-HFD mice in which CD8+ T cells promote non-fibrotic liver damage7, CD8+ 141 
T cells don’t contribute to NASH in MUP-uPA mice, which are highly fibrotic and depend on 142 
macrophage TNF production. 143 
IgA+ cell and CTL interplay in HCC development  144 
 After 7 months of HFD, MUP-uPA mice developed HCC15, which contained numerous 145 
(usually 50-100/tumor) non-recurrent coding mutations in pathways that are mutated in human 146 
HCC (Fig. 2d; Extended Data Fig. 6a). Mutational signatures were almost identical between 147 
mouse and human HCC (Extended Data Fig. 6b)20. Pathways and responses that were 148 
upregulated during MUP-uPA NASH to HCC progression were similar to those altered in human 149 
HCC (Extended Data Fig. 6c,d).  150 
Cd8a ablation greatly accelerated HCC development: 12.5% of MUP-uPA/Cd8a-/- mice 151 
showed a single large tumor (>0.4 cm) at 3 months and 27% contained such tumors at 6 152 
months, at which point MUP-uPA or MUP-uPA/Iga-/- mice had no large tumors (Fig. 2e-g, 153 
Extended Data Fig. 6e,f). Similar observations were made in STAM mice (Fig. 2h,i). MUP-154 
uPA/Cd8a-/- tumors had typical HCC histology and their early appearance was confirmed by 155 
whole liver RNA-seq, showing elevated expression of HCC markers (Extended Data Fig. 6e-g), 156 
that are also expressed by HCC progenitor cells (HcPC)21. HCC development and burden were 157 
greatly reduced in IgA-deficient mice, some of which contained no large tumors at 11 months 158 
(Fig. 2e-g). Complete B cell deficiency, replacement of the entire immunoglobulin repertoire with 159 
hen egg lysozyme (HEL)-specific IgM, B cell-specific TGF-β receptor 2 ablation and PD-L1/2 160 
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deficiency also inhibited HCC development (Fig. 2f-i; Extended Data Fig. 6h-j). By contrast, 161 
ablation or depletion of CD8+ T cells in IgA-deficient mice restored HCC development, whereas 162 
absence of T and B cells (Rag1-/-) enhanced HCC development as effectively as Cd8a ablation 163 
(Fig. 2f,i,j; Extended Data Fig. 6k,l), indicating that without T cells, B or IgA+ cells don’t promote 164 
tumorigenesis. IgA ablation enhanced immune activation and graft rejection markers (Extended 165 
Data Fig. 6c,m). At the time of HCC analysis, Cd8a-/- livers were more fibrotic than MUP-uPA or 166 
STAM livers, but steatosis didn’t differ between WT, Cd8a-/- and Iga-/- mice (Extended Data Fig. 167 
6i,j,n). These results strongly suggest that reduced tumorigenesis after Iga ablation is due to 168 
CTL reactivation. Indeed, adoptive transfer of T, but not T+B, cells into MUP-uPA/Rag1-/- mice 169 
suppressed tumorigenesis (Fig. 2j; Extended Data Fig. 6o-q). 170 
Gut microbes promote HCC development 171 
IgA dimers secreted by intestinal IgA+ PC that maintain microbial homeostasis enter the 172 
intestinal lumen via the polyimmunoglobulin receptor (PIgR)22. Gut microbial components reach 173 
the liver via the portal circulation and enhance inflammation, fibrosis and carcinogenesis23,24. To 174 
identify gut-specific secretory IgA functions, we examined NASH-induced HCC in Pigr-/- mice. 175 
Unlike IgA ablation, PIgR deficiency potentiated tumorigenesis and increased circulating and 176 
liver IgA (Fig. 2h; Extended Data Fig. 6h,r,s). Congruently, broad spectrum antibiotics (Abx), 177 
which reduced gut bacteria by >90% (Extended Data Fig. 7a), attenuated HCC development in 178 
all mouse strains (Fig. 2f). Abx reduced weight gain, liver steatosis and inflammation, but had a 179 
marginal effect on liver fibrosis and damage, barely affected liver CD8+ effector cells and 180 
CD19+B220+ cells, and as expected, reduced liver and circulating IgA and Th17 cells (Extended 181 
Data Fig. 7b-j). HFD-feeding induced microbial dysbiosis; but even in HFD-fed mice, immune 182 
alterations dominantly modulated microbiota composition and fecal metabolites (Extended Data 183 
Fig. 7k-r). Despite opposing effects on tumorigenesis, the microbiota of Iga-/-, Pigr-/- and 184 
IgHEL/MD4 mice showed similar deviations from the WT or Cd8a-/- microbiota based on 185 
unweighted UniFrac distances (Extended Data Fig. 7r).  186 
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IgA+ plasmocytes suppress CTL activation 187 
 Liver IgA+ cells directly suppressed CTL activation. Ovalbumin (Ova)-expressing HCC-188 
derived dih cells presented the SIINFEKL peptide on H-2Kb and activated OT-I CD8+ T cells 189 
(Extended Data Fig. 8a,b). RFP-(controls) and Ova-expressing cells were starved overnight to 190 
induce some (5%) cell death and antigen release and incubated with or without B cells from WT, 191 
Pdl1/2-/- or SW-HEL25 mice. TGF-β1 and CTGF were added to induce IgA CSR and after their 192 
removal, OT-I cells were added. Whereas WT B cells modestly inhibited basal OT-I cell 193 
proliferation, this was strongly potentiated by TGF-β1+CTGF (Extended Data Fig. 8b). By 194 
contrast, Iga-/-, Pdl1/2-/- and SW-HEL B cells had compromised inhibitory activity, indicating a 195 
requirement for PD-L1 and antigen-specific BCR for CD8+ T cell suppression. Iga-/- and SW-196 
HEL B cells produced low PD-L1 levels, whereas dih cells incubated with IFNγ-producing OT-I 197 
cells expressed more PD-L1 (Extended Data Fig. 8c,d). Cancer cell killing by OT-I cells required 198 
Ova expression and was attenuated by WT, but not Iga-/-, Pdl1/2-/- or SW-HEL B cells (Extended 199 
Data Fig. 8e,f). Incubation with dih-Ova cells, TGF-β1 and CTGF, with or without OT-I cells, 200 
induced IgA production by WT B cells and to a lesser extent in SW-HEL B cells, but not in 201 
Pdl1/2-/- B cells, some of the secretory IgA was directed against Ova (Extended Data Fig. 8g). 202 
WT, but not Iga-/-, Pdl1/2-/-, or SW-HEL B cells suppressed CD8+ T cell expansion (Extended 203 
Data Fig. 8h). Similar results were obtained using Ova-expressing TRAMP-C2 cells14, indicating 204 
that suppression of OT-I CD8+ T cells by IgA+ cells was not unique to HCC (Extended Data Fig. 205 
8i,j). These results suggest that effective T cell suppression required IL-10, which was also 206 
needed for maximal IgA production. 207 
 IgA+ cells also inhibited CTL activation in vivo. At 3 months, HFD-fed MUP-uPA/Iga-/- 208 
mice had significantly more liver CD8+ T cells than MUP-uPA mice, and this was maintained at 209 
later time points (Fig. 3a,b; Extended Data Fig. 8k,l). Importantly, MUP-uPA mice on HFD had 210 
more effector and degranulating CD8+ T cells at 3 months than at 6 months; however, such a 211 
difference wasn’t found in MUP-uPA/Iga-/- mice, which showed even more activated CTLs at 11 212 
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months (Fig. 3c-e, Extended Data Fig. 8m-r). Correspondingly, IgA ablation decreased the 213 
number of PD-1+Tim3+CD8+ exhausted T cells (Fig. 3f). These results suggest that prior to IgA+ 214 
plasmocyte accumulation CD8+ T cells are engaged in immunosurveillance, thereby explaining 215 
absence of HCC in young MUP-uPA mice and its appearance after IgA plasmocyte 216 
accumulation and CD8+ T cell exhaustion. As reported26, HFD-feeding decreased liver CD4+ T 217 
cells, but increased relative Th17 and Treg cell amounts, as well as Tfh-like (PD1+CXCR5+CD4+) 218 
cells (Fig. 3g, Extended Data Fig. 8s-u). IgA ablation had a minimal effect on these changes, 219 
although it increased HCC-infiltrating Th1 cells (Fig. 3h), while having little effect on liver B cells 220 
and increasing liver IgG+ and CD138+ cells during NASH (6m) but not HCC (11m) (Extended 221 
Data Fig. 8v-y).  222 
PD-L1 blockade induces HCC regression 223 
 We placed MUP-uPA and MUP-uPA/Iga-/- mice on HFD for 7 months to establish HCC 224 
growth and injected them weekly with a PD-L1 blocking antibody (αPD-L1) or a control 225 
(LALAPG) that doesn’t block PD-1 engagement (Extended Data Fig. 2a). PD-L1 blockade 226 
reduced tumor multiplicity and load, and most large tumors had disappeared (Fig. 4a,b). The 227 
treatment reduced liver-to-body ratio without affecting body weight or reducing serum IgA levels 228 
(Extended Data Fig. 9a-c), further demonstrating HCC eradication. This beneficial effect was 229 
associated with tumoral lymphocyte accumulation (Fig. 4c,d) and decreased steatosis 230 
(Extended Data Fig. 9d). αPD-L1 nonresponsive tumors lacked immune cells and were 231 
encapsulated by fibrotic tissue (Extended Data Fig. 9e). PD-L1 blockade substantially 232 
decreased liver IgA+IL-10+ cell abundance, probably due to disrupted PD-L1:PD-1 B cell-Tfh 233 
interactions, needed for plasma cell maturation27, and increased CD8+ T cells, including 234 
proliferating cells expressing IFNγ and GrzB (Fig. 4e,f). PD-L1 neutralization didn’t decrease 235 
tumor burden in MUP-uPA/Iga-/- or MUP-uPA/Cd8a-/- mice (Fig. 4a; Extended Data Fig. 9f), 236 
indicating that it acts via IgA+ cells and targets CD8+ T cells.  237 
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Clonal expansion of liver CD8+ T cells 238 
 We sequenced CD8+ TCR α and β chains from livers and spleens of HCC-bearing MUP-239 
uPA and MUP-uPA/Iga-/- mice and age-matched controls. In HCC-bearing mice the TCR 240 
repertoire was much less diverse in liver than in spleen (Fig. 4g,h, left; Extended Data Fig. 9g). 241 
The liver TCRαβ repertoire of control BL6 mice was less diverse than that of HCC-bearing mice 242 
and was unaffected by HFD feeding (Fig. 4g,h, right; Extended Data Fig. 9h,i). Although IgA 243 
ablation enhanced CD8+ T cell activation, it barely effected liver/HCC CD8+ cell TCR diversity 244 
(Fig. 4g,h; Extended Data Fig. 9i,j). PD-L1 neutralization clonally expanded liver/HCC CD8+ T 245 
cells, some of which were AFP directed (Fig. 4i; Extended Data Fig. 9k-m). AFP-specific CD8+ T 246 
cells were elevated after αPD-L1 treatment or IgA ablation. By contrast, HFD-fed BL6 mice 247 
contained more AFP-specific CD4+ T cells than HCC-bearing mice, in which CD4+ cell 248 
abundance was unaffected by αPD-L1 or IgA ablation (Extended Data Fig. 9n). B cell receptor 249 
(BCR) sequencing showed clonal expansion of a small repertoire of liver-infiltrating IgA- and 250 
IgM-producing cells in HCC-bearing mice (Extended Data Fig. 10a,b). Both T and B cell clonal 251 
expansion could be driven by tumor antigens.  252 
Discussion 253 
CD8+ T cells can eradicate established tumors, but evidence that adaptive immunity 254 
curtails early cancer development is scant4, or has been derived from chemically-induced 255 
mouse sarcomas that evade destructive T cell responses by downregulating rejection antigens3. 256 
Our results provide one of the strongest and most direct demonstrations that adaptive immunity 257 
actively prevents cancer emergence. In fact, liver immunosurveillance is so effective that without 258 
immunosuppressive IgA+ cells that directly inhibit HCC-directed CTL activity, NASH to HCC 259 
progression is severely hampered. Immunosuppressive IgA+ cells are byproducts of chronic 260 
liver inflammation, which causes Tfh accumulation and elevated TGF-β, IL-21 and IL-33, and 261 
are distinct from intestinal IgA+ B cells that maintain microbial homeostasis and suppress liver 262 
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inflammation and tumorigenesis. PD-L1, first shown to prevent excessive CD8+ cell activation 263 
during viral infections28, is also needed for generation of immunosuppressive IgA+ cells29. Given 264 
that intestinal IgA suppresses inflammation and tumorigenesis, the reduction in NASH-induced 265 
tumorigenesis in Iga-/- mice is partially compromised by the increase in liver inflammation, and 266 
could therefore be greater than actually apparent.  267 
 Our ability to unravel the cancer preventive effect of adaptive immunity is likely due to a 268 
mouse model that closely mimics NASH-driven human HCC and does not rely on engineered 269 
mutations and tumor suppressor ablation that trigger rapid malignant progression without 270 
additional neo-antigen generating genetic alterations30. NASH-driven liver carcinogenesis 271 
depends on ongoing stress and inflammation15,23, which underlie human HCC, whose 272 
mutational landscape and signature are almost synonymous with MUP-uPA HCC20. The 273 
immunopathogenesis of NASH to HCC progression in MUP-uPA and STAM mice is also very 274 
similar to human NASH-driven HCC, with the pre-cancerous liver exhibiting accumulation of PD-275 
L1 and IL-10 expressing IgA+ cells, paralleling the appearance of inflammation-induced HcPC. 276 
IgA+ cell depletion, via Iga, Tgfbr2 or PD-L1 ablation or blockade, enhances HcPC eradication 277 
and regression of established tumors through CTL activation, despite the potential increase in 278 
intestinal dysbiosis. Liver-infiltrating IgA+ cells don’t affect liver injury and are not unique to 279 
NASH, as they are also found in ASH and other chronic hepatides. Another feature of human 280 
NASH and our mouse models is accumulation of CD8+ T cells, whose ablation resulted in a 7-8-281 
fold reduction in tumor latency, suggesting they eradicate HCC cells as soon as they appear. 282 
Although hepatic CD4+ T cells decline in HFD-fed MUP-uPA mice, as found previously26,31, the 283 
frequency of Th17 and Treg cells that are cancer supportive, increases. Nevertheless, the key 284 
immune-related HCC-promoting mechanism triggered during NASH entails IgA+ cell generation. 285 
Further evidence for the immunosurveilling function of CD8+ T cells is provided by their 286 
oligoclonality and reduced diversity in HCC, and their reinvigoration and expansion after IgA+ 287 
cell depletion. Our results appear applicable to human HCC, as suggested by a clinical trial that 288 
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revealed the utility of PD-1 blockade with only one patient developing treatment-related 289 
hepatitis32, showing that activated CD8+ T cells rarely damage the liver.  290 
 291 
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Figure Legends 394 
Figure 1: NASH-induced IgA+ plasmocyte accumulation in human and mouse liver 395 
(a,c) Liver biopsies from NASH/NAFLD patients (n=18) stained for IgA and CD8. Staining 396 
intensity was graded from 0 to 3 and plotted against serum IgA (a) or Kleiner fibrosis scores (c). 397 
The data were validated in 2 different experiments. (b) Serum and liver IgA concentrations (IHC 398 
scores) plotted against Kleiner fibrosis scores, and were further validated in two different human 399 
cohorts (n=502 and 96; Extended Data Fig.1a,b). (d) Mice of indicated genotypes, ages and 400 
treatments were analyzed for serum IgA (n=4-20). (e,f) Liver IgA+ cell (percentage and absolute 401 
cell numbers) in different mouse strains and treatment groups (n=6-31). (g) Representative 402 
images of paired human non-tumor liver and tumor sections (n=4) stained for IgA and CD8. (h) 403 
STAM-B6 liver sections were stained for CD3, CD8 and IgA, and counterstained with DAPI 404 
(n=3). Magnification bars: 25-75 μm. Arrows indicate IgA+ and CD3+CD8+ cells in g,h. The data 405 
were validated at least in 2-3 experiments. Linear regression analysis was used to determine 406 
the correlation between serum IgA and IgA IHC score (a). One-way ANOVA (Means±SEM; 407 
panel b,c), two-sided T-test (Means±SEM; panel d) and Mann-Whitney test (Median; panel e,f) 408 
were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not significant. 409 
Specific n-values are shown in panels d-f. 410 
Figure 2: IgA ablation inhibits while CD8a ablation accelerates HCC appearance 411 
(a) Splenic and liver cells from indicated mice (n=3-12) were stained after ex vivo stimulation 412 
and analyzed by flow cytometry (FC). % of IgA+ cells expressing IL-10 and PD-L1. (b,c) Splenic, 413 
liver and intestinal cells from Il10-GFP/MUP-uPA mice (n=6-12) were stained and FC analyzed. 414 
(b) Representative FC analysis of Il10-GFP expression in liver B cells and PC subpopulations. 415 
(c) Representative FC plots and % of GFP+ cells in IgA+ subpopulations. (d) Mutated genes in 416 
human HCC based on COSMIC Database and MUP-uPA-HFD mice are compared. Driver 417 
genes20 are marked (*red). (e) Representative gross liver morphology and large tumor (T) 418 
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incidence (>0.4 cm) at different time points are shown. (f,g) Tumor numbers (n=4-31) (f) and 419 
volumes (n=9-38) (g) in 11m old HFD-fed MUP-uPA mice. When indicated, mice were treated 420 
with broad spectrum antibiotics (Abx) from 6 to 11m. (h,i) Tumor multiplicity in indicated BL6 (h) 421 
or FVB (i) STAM mice was determined at 25 or 20 weeks of age, respectively (n=3-19). 422 
Experiments were repeated at least 3 times. STAM-Iga-/- mice were injected weekly with anti-423 
CD8 (n=3) for 5 weeks. (j) Splenocytes from WT-BL6 (T+B cells) or μMT-/- (T cells) mice were 424 
transferred into MUP-uPA/Rag1-/- mice (n=4 per transfer). After one month, tumor numbers and 425 
volumes were determined. Experiments were performed twice. Tumor volumes (g,j-right) are 426 
plotted logarithmically, and min to max with all points are shown. Two-sided T-test 427 
(Means±SEM; panel j-left) and Mann-Whitney test (Median; panel a,c,f-i,j-right) were used to 428 
determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not significant. Specific n-values are 429 
shown in panel a,c,f-j, and Supplementary Table 1-2. 430 
Figure 3: Liver IgA+ cells induce CD8+ T cell exhaustion 431 
(a-f) Liver cells from indicated 3, 6 and 11m old mice (n=3-18 per group) were stained and FC 432 
analyzed. Shown are % of CD8+ T cells (a), absolute CD8+ T cell number per gram liver (b), and 433 
% of CD44+CD8+ effector T cells (c). (d-e) Liver CD8+ T cells from indicated mice (n=3-10) were 434 
stimulated with PMA/Ion and stained as indicated. % of CD8+ T cells positive for CD44, IFNγ 435 
and TNF (d), IFNγ and CD107a (e). (f) % of CD8+Tim-3+PD-1+ T cells at 6 and 11m (left), and 436 
PD-1+ T cells 11m (right). (g-h) Liver cell suspensions were stained for CD4 (g) and CD4 and 437 
IFNγ (h). The gating scheme is indicated above each panel. The data were validated at least in 438 
3 independent experiments. Two-sided T-test (Means±SEM; panel f-left) and Mann-Whitney 439 
test (Median; panel a-h,f-right) were used to determine significance. *P<0.05; **P<0.01; 440 
***P<0.001; n.s. not significant. Specific n-values are shown in panels. 441 
 442 
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Figure 4: PD-L1 blockade reactivates and expands antigen-specific CD8+ T cells to induce 443 
HCC regression 444 
Tumor-bearing MUP-uPA mice (n=7-10) were given 8 weekly injections of a blocking (αPD-L1) 445 
or control (LALAPG) PD-L1 antibodies or left untreated. Tumor number (a), representative gross 446 
liver morphology (b) and tumor histology (c). Arrow in (c) shows a typical inflammatory infiltrate 447 
(magnification bars: 100 μm). (d) Liver sections were stained for CD3 and CD8 and examined 448 
by fluorescent microscopy (magnification bars: 50 μm). Experiments were repeated at least 2-3 449 
times. (e,f) Liver CD45+ cells were stained as indicated and FC analyzed. (g,h) CD8+ T cells 450 
were sorted from spleens and livers of indicated mice (n=9) and were sequenced for TCR α (g) 451 
and β (h) chain CDR3 region (18 samples). Panels show clonality and frequency of top 50 TCR 452 
α and β sequences. (i) Similar analysis was performed on CD8+ T cells from spleens and livers 453 
of αPD-L1 (8 samples) or control (-) treated HCC-bearing mice. Panel shows % of productive 454 
unique TCRα sequences. Two-sided T-test (Means±SEM; panel g-i) and Mann-Whitney test 455 
(Median; panel a,e,f) were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. 456 
not significant. Specific n-values are shown in panel a,e,f. 457 
 458 
 459 
 460 
 461 
 462 
 463 
 464 
 465 
 466 
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Methods 467 
Animal models 468 
C57BL/6 and FVB/NJ control mice were purchased from Charles River Laboratories and Cd8a-/-469 
, Il10-GFP reporter mice33 and μMT-/- mice34, were purchased from the Jackson Laboratory. IgA 470 
gene-deficient (Iga-/-) mice35 were obtained from Baylor College of Medicine. MUP-uPA mice, 471 
were previously described15 and were crossed with B cell-deficient (μMT-/-) mice34, CTL-deficient 472 
(Cd8a-/-) mice36, Iga-/- or Rag1-/-37 mice. B cell-deficient (JH-/-)38, IgHEL/MD439 [monoclonal for B 473 
cell receptor (BCR) specific for hen egg lysozyme; HEL], Cd8a-/-;Iga-/- double knockout, Pdl1/2-/- 474 
(Genentech, San Francisco, CA), and Pigr-/-40 mice were subjected to STAM, MCD and CCl4-475 
protocol. Cd19-Cre mice were crossed to Tgfbr2F/F 41 with both BL6 and FVB/NJ background, 476 
and were also used as indicated. Cd8a-/-, Iga-/- and JH-/- were crossed to FVB/NJ for at least 10 477 
generations and were used for experiments in both BL6 and FVB/NJ backgrounds. Iga-/-, Pdl1/2-478 
/-, SW-HEL (expressing HEL-specific monoclonal BCR that can switch to IgG and IgA)42 and 479 
OT-I mice43 (Taconic) were used for cell culture experiments. All mice were maintained in filter-480 
topped cages on autoclaved food and water at the UCSD animal facility and were used in 481 
accordance with UCSD and NIH guidelines and regulations, particularly for experimental 482 
Neoplasia, which includes tumor size limits (not exceeding 2 cm for a single tumor) and 483 
monitoring parameters. Tumor volumes were calculated as width2 x length / 2, and for multiple 484 
spontaneous liver tumors the volumes of single tumors were added for a total tumor volume. 485 
When indicated, mice were fed high fat diet (HFD) starting at 8 weeks of age for the MUP-uPA 486 
HFD-fed model15 or at 4 weeks for the STAM model44, respectively (Extended Data Fig. 2a). In 487 
MCD-HFD model, indicated mice were kept on a methionine and choline deficient (MCD) with 488 
60 kcal% fat, for 4 weeks (Extended Data Fig. 2a). In CCl4 model, indicated mice were injected 489 
intraperitoneally (i.p.) with CCl4 bi-weekly for 8 weeks (Extended Data Fig. 2a).  490 
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Mouse treatment studies were “matched design control trials”. Accordingly, mice were randomly 491 
chosen and paired based on gender (male), weight and age. An identification code was 492 
assigned to each mouse and the investigators were blinded to treatment allocation at the time of 493 
analysis. Mice that did not gain weight or showed sign of dermatitis, a rarely observed 494 
phenotype in MUP-uPA HFD-fed mice, were excluded from the study. The numbers of mice 495 
used in experiments are shown in Supplementary Table 1 (MUP-uPA model) and 496 
Supplementary Table 2 (STAM, MCD and CCl4 models). MUP-uPA (n=543 mice), STAM (n=123 497 
mice), MCD (n=65 mice) and CCl4 (n=82 mice) models were analyzed in 50, 15, 3 and 6 498 
experiments, respectively. Most of the basic characterization of control BL6, Iga-/- and Cd8a-/- 499 
mice is shown in Extended Data Fig. 10. These groups were compared to exclude the general 500 
effect of IgA and CD8 deficiencies on weight gain and immune status. Non-treated control mice 501 
that have been used are not shown in Supplementary Table 1 and 2, but mentioned in each of 502 
the Figure legends. 503 
Flow cytometry  504 
Cell suspensions were prepared from livers, spleens, intestine and visceral fat as described14. 505 
Lymphocytes were isolated from human blood using Ficoll-Paque PLUS (GE Healthcare Life 506 
Science) according to manufacturer’s recommendations. For lymphocyte isolation, tissues (liver, 507 
intestine and HCC-tumors) were cut into small pieces and incubated in dissociation solution 508 
[DMEM medium supplemented with 5% FBS, collagenase type I (200 U/mL), collagenase type 509 
IV (100 U/mL) and DNase I (100 μg/mL)] for 30 min at 37° C. After incubation, cell suspensions 510 
were passed through a 40 μm cell strainer and washed twice. To block Fc-mediated 511 
interactions, mouse cells were pre-incubated with 0.5-1 μg of purified anti-mouse CD16/CD32 512 
per 100 μL and human cells were incubated with FcR blocking reagent (Miltenyi Biotec). 513 
Isolated cells were stained with labeled antibodies in PBS with 2% FBS and 2 mM EDTA or cell 514 
staining buffer (Biolegend). Dead cells were excluded based on staining with Live/Dead fixable 515 
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dye (FVD-eFluor780, eBioscience). For intracellular cytokine staining, cells were restimulated 516 
with AFP (5 μg/mL) or cell stimulation cocktail [eBioscience; containing phorbol 12-myristate 13-517 
acetate (PMA) and ionomycin (Ion)], in the presence of a protein transport inhibitor cocktail 518 
containing Brefeldin A and Monensin (eBioscience). For measurement of IL-10 production by B 519 
cells, LPS was added to the above described PMA/Ion medium. For CD107a measurement, a 520 
staining antibody was added to the culture during the stimulation. After 4-5 hrs, cells were fixed 521 
and permeabilized either with BDTM Cytofix/Cytoperm reagent for cytokine staining or 522 
eBioscience™ Foxp3/Transcription Factor staining buffer for combined staining of cytokines 523 
with transcription factors. After fixation/permeabilization, cells were stained with labeled 524 
antibodies of interest. Cells were analyzed on a Beckman Coulter Cyan ADP flow cytometer. 525 
Data were analyzed using FlowJo 10.2 software (Treestar). Absolute numbers of particular 526 
immune cells in spleen were calculated by multiplying the total cell numbers from one spleen by 527 
the percentages of the particular cell type amongst total cells. Absolute numbers of particular 528 
immune cells (e.g. IgA+ and CD8+ cells) in livers were calculated by multiplying the cell number 529 
in one liver portion by the percentages of the corresponding cell type in total liver cells divided 530 
by the weight of the analyzed liver fragment (cell number per gr liver). 531 
Human specimens and analysis  532 
It has previously been demonstrated that serum IgA levels correlate with hepatic fibrosis stage 533 
in the Newcastle NAFLD Clinic cohort13. A larger NAFLD cohort from Newcastle (n=502) was 534 
analyzed and is shown in Extended Data Fig. 1a. Furthermore, the study included 18 patients 535 
with biopsy-proven NAFLD (11 in initial phase, 7 in second phase) and 5 patients with HCC who 536 
attended the Newcastle Hospitals fatty liver clinic between 1999 and 2016. NAFLD cases were 537 
selected for this study based on high serum IgA/advanced fibrosis (n=9) vs. low serum IgA/mild 538 
fibrosis (n=9). Liver biopsies were performed as part of the investigation of abnormal liver 539 
function tests or to stage disease severity in patients with ultrasound evidence of NAFLD. 540 
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Clinical and laboratory data were collected from the time of liver biopsy. Alternate diagnoses 541 
were excluded, including increased alcohol intake (males and females consuming greater than 542 
21/14 units of alcohol per week [>30/20 g/day ethanol], respectively, were excluded), as were 543 
any individuals with chronic viral hepatitis (hepatitis B and hepatitis C), autoimmune liver 544 
diseases, hereditary hemochromatosis, α1-antitrypsin deficiency, Wilson’s disease and drug 545 
induced liver disease. In addition, patients in whom immunoglobulins were not available within 6 546 
months of liver biopsy were excluded. Blood test results were taken from the time of liver biopsy 547 
or within 6 months. The normal ranges for serum IgA, IgG and IgM were 0.64-2.97 g/L, 5.8-15.4 548 
g/L and 0.71-2.3 g/L, respectively. Percutaneous liver biopsies were performed using a 549 
Menghini needle or an 18G BioPince liver biopsy system (Medical Devices Technologies, 550 
Gainville, Florida, USA). Histological scoring was performed according to the NIH NAFLD 551 
Clinical Research Network criteria. Liver biopsy specimens were assessed by experienced 552 
hepatopathologists (A.D.B., Q.M.A. & J.B.). In the current study, FFPE liver tissue was stained 553 
for IgA, CD8 and CD20 and assessed by a single histopathologist (J.B.) using a semi-554 
quantitative score. All statistical analyses were performed using SPSS software version 22.0 555 
(SPSS Inc, Chicago, USA). All the Newcastle patients have given informed consent. Ethical 556 
approval to establish the Newcastle HPB Biobank from which these samples were used was 557 
received from the “Newcastle & North Tyneside 1 Research Ethics Committee” REC reference 558 
10/H0906/41.  559 
In a second cohort from UCSD (n=96), serum IgA, IgM and IgG levels from corresponding 560 
patients were analyzed in Supplementary Table 3.  561 
Anonymized samples from consented human subjects were provided with UCSD IRB Ethical 562 
committee approval. Liver biopsy assessment was performed by a trained and experienced 563 
hepatopathologist (R.L.). All patients had a clinical indication for a liver biopsy and underwent a 564 
22 
 
core biopsy of the liver using a 16 gauge bio-pince needle. All biopsies were read using the 565 
NASH CRN Histologic Scoring System45.  566 
Immunostaining 567 
Tissues were embedded in Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA, USA) 568 
and snap-frozen. Tissue sections were fixed in cold acetone/methanol or 3% PFA for 3-10 min 569 
and washed with PBS. Slides were blocked with 1x PBS/1% normal donkey or goat serum for 570 
surface staining or 0.2% gelatin (from cold water fish skin; Sigma-Aldrich)/PBS/1% normal 571 
donkey or goat serum for intracellular staining for 30 min. Sections were incubated with primary 572 
antibodies for 1 or 12 hrs at RT or 4 °C, respectively. After washing with PBS, secondary 573 
antibodies were added for 1 hr at RT. As negative controls, samples were incubated with 574 
isotype-matched control antibodies or secondary antibodies only. After staining with DAPI, 575 
sections were covered with Vectashield Mounting Medium (Vector Laboratories, Burlingame, 576 
CA, USA). Paraffin-embedded tissue sections were subjected to de-paraffinization and 577 
rehydration, and then were immersed in a pre-heated antigen retrieval water bath with a pH 6.1 578 
citrate buffer, or Dako Target Retrieval Solution for 20 min at 95-96 °C. All stainings were done 579 
according to manufacturer’s protocols (Vector Laboratories). Nuclei were lightly counterstained 580 
with a freshly made haematoxylin solution then further washed in water. Sections were 581 
examined using an Axioplan 200 microscope with AxioVision Release 4.5 software (Zeiss, Jena, 582 
Germany) or TCS SPE Leica confocal microscope (Leica, Germany). 583 
Histology 584 
Livers were fixed in 10% neutral-buffered formalin or 4% paraformaldehyde, embedded in 585 
paraffin, sectioned, stained with hematoxylin and eosin (H&E), Sirius Red (SR) and processed 586 
for immunohistochemistry (IHC). For frozen-block preparation, tissue was embedded in Tissue-587 
Tek OCT compound, and were stained with Oil Red O (ORO) and H&E. Whole slide images 588 
were analyzed using a Hamamatsu 2.0-HT Digital slide scanner and processed using the NDP 589 
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View Hamamatsu software (Hamamatsu Photonics K. K., EU, Japan, USA). For Sirius Red 590 
analysis, areas of at least 1 cubic mm were quantitated using Image J software (NIH, Maryland, 591 
USA) and normalized for vascularization and lipid accumulation using corresponding H&E 592 
areas. For Oil Red O analysis, multiple images (2-3) were examined for each tissue section 593 
using an Axioplan 200 microscope with a 20x objective with AxioVision Release 4.5 software 594 
and quantitated as averages using the Image J software.  595 
Antibodies 596 
Antibodies specific for the following antigens were used (anti-mouse were abbreviated as “m” 597 
and anti-human as “h”): Tim-3 (mB8.2C12-AlexaF647; hF38-2E2-PerCP-eF710); CD138 (m281-598 
2-PE/APC; hDL-101-APC); IgA (mA-6E1-PE/FITC; m11-44-2-Biotin; mRMA-1; hIS11-8E10-599 
FITC; DAKO hA0262); CD8α (m53-6.7-PerCp-Cy5.5/PE-Cy7; hRPA-TB-PE; h4B11); CD45 600 
(m30-F11-V500; hHI30-eF450); CD20 (mAISB12-PE); CD44 (mIM7-PE/FITC/eF450); CD4 601 
(mRM4-5-eF450; mGk1.5-FITC/PE/PE-Cy7; hRPA-T4-APC); B220 (mRA3-6B2-eF450/FITC); 602 
CD19 (meBio1D3-eF660/PE-Cy7; hHIB19-PE); IgM (mII/41-PE-Cy7; hSA-DA4-eF450); IgD 603 
(m11-26c.2a-Pacific-Blue; m11-26c-PerCP-eF710); TNF (mMP6-XT22-FITC/PE); IFNγ 604 
(mXMG1.2-eF660); GrzB (mNGZB-eF660); CD107a (meBio1D4B-PE); PD-1 (mJ43-605 
eF450/FITC; mRMP1-30-APC; hMIH4-FITC); PD-L1 (mMIH5-PE-Cy7/PE; hMIH1-PE-Cy7); 606 
FAS-L1 (mMFL3-FITC); Ki-67 (mSolA15-eF450); IgG2a (m2a-15F8-FITC/APC; mRMG2a-62-607 
PE); IgG1 (mM1-14D12-eF450; mRMG1-1-FITC); IL-10 (mJES5-16E3-PE); CD11c (mN418-608 
eF450/PE); CD11b (mM1/70-eF450/eF660); MHCII (mM5/114.15.2-FITC/PE); Gr-1 (m1A8-609 
Ly6G-PerCP-eF710); IL-17 (meBio17B7-PE-Cy7); Foxp3 (mFJK-16s-eF450); Perforin 610 
(meBioOMAK-D-FITC); CXCR5 (mSPRCL5-PE/APC/Biotin); CD62L (mMEL-14-PE/APC); 611 
SIINFEKL/H-2Kb (meBio25-D1.16-APC); F4/80 (mBM8-PE/FITC); anti-Biotin (BK-1/39-PE); 612 
CD5 (m53-7.3-FITC/eF450) and NK1.1 (mPK136-APC); CD31 (390-eF450) (most from 613 
eBioscience and Biolegend); pAb rabbit to CD3 (DAKO, IS503); and αSMA (m-ab5694; DAKO, 614 
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h1A4). The following Alexa 594-, Alexa 647-, Alexa 488-conjugated secondary antibodies were 615 
used: donkey anti-rat IgG, donkey anti-rabbit IgG, donkey anti-goat IgG and goat anti-rat IgG 616 
(Molecular Probes, Invitrogen).  617 
Cell culture experiments for analyzing the ex vivo immunosuppression and IgA CSR 618 
Two inducible ovalbumin (Ova)-P2A-red fluorescence protein (RFP)-expressing dih10 and 619 
dihXY HCC cell lines and prostate cancer cell line TRAMP-C2 (ATCC) were developed (dih10-620 
Ova-RFP, dihXY-Ova-RFP, TRC2-Ova-RFP), and ovalbumin processing confirmed, which 621 
results in presentation of SIINFEKL peptide on MHCI (H-2Kb). This peptide can be recognized 622 
by OT-I CD8+ T cells, which express a high affinity TCR specific for ovalbumin. Both dih cell 623 
lines were established previously in our laboratory using DEN-induced HCC and were regularly 624 
tested for mycoplasma (MycoAlertTM Mycoplasma Detection kit) and genomic PCR to confirm 625 
their characterization46.  626 
Dih-RFP, TRC2-RFP or ova-expressing dih, TRC2 cells were starved over or treated with low 627 
dose chemotherapy for 24 hrs (~5-8% cell death). After that, the medium was changed and 628 
magnetic beads sorted B cells (7×105 / well) from either WT, Pdl1/2-/-, Il10-/- or SW-HEL 629 
(monoclonal BCR specific for hen egg lyzosyme-HEL, however, which can still switch to other 630 
immunoglobulin classes upon BCR and/or cytokine signaling) mice were added in the presence 631 
of TGF-β1 (5 ng/mL) and CTGF (3 ng/mL), for an additional 24 hrs. After TGF-β1/CTGF 632 
removed, CFSE-labeled OT-I T cells (specific for ovalbumin) were added to the cultures (3×105 / 633 
well) that either contained or did not contain the B cells described. T cells were isolated from 634 
Rag1-/-/OT-I mice using CD8 negative selection beads and their proliferation was analyzed on 635 
days 3, 4, 5, 6 and 7. The proliferation and the amount of CFSE-labeled OT-I CD8+ cells were 636 
analyzed by flow cytometry and quantitated. IgA concentrations in the culture supernatants were 637 
determined using ELISA. Induction of cancer cell death was analyzed using LIVE/DEAD cell 638 
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staining dyes (FVD-eF780, eBioscience). Percentage of CD19+ cells, antigen presentation 639 
(SIINFEKL/H-2Kb) and PD-L1 expression were also analyzed using flow cytometry. 640 
ELISA and colorimetric protein detection 641 
Mouse IgA and IgG ELISA kits from eBioscience were used according to manufacturer’s 642 
protocols. Human serum IgA and IgG were measured in the first cohort from Newcastle, as 643 
described previously13, or in cohort two at the UCSD Medical Center Laboratory. ELISA for the 644 
determination of OVA-specific IgA (Anti-OVA-IgA) in the co-culture experiment was performed 645 
by adding culture supernatant to the ovalbumin coated wells, incubated at 4°C overnight, and 646 
washed with PBST. Rat anti-mouse IgA antibody (RMA-1, Biolegend) was added and incubated 647 
at RT for 1 hr, thereafter, anti-rat HRP-conjugated antibody was added for further 30 min. After 648 
PBST washing, 1×TMB was added and the reaction was stopped with 2N H2SO4, followed by 649 
detection in a microplate reader at 450 nm. Mouse serum ALT was measured using ALT (GPT) 650 
reagent (Thermo Scientific). Triglyceride and total cholesterol contents were measured using 651 
Triglyceride Colorimetric Assay Kit (Cayman Chemical) and Cholesterol Fluorometric Assay kit 652 
(Cayman Chemical) according to the manufacturer’s instructions, respectively. 653 
Glucose tolerance test 654 
Mice were transferred to clean cages with no food or feces in hopper or bottom of cage and 655 
fasted for approximately 6 hrs with access to drinking water. Small drops of blood were obtained 656 
from tail cuts and assessed for baseline glucose levels using a One-touch Ultra 2 (Lifescan, 657 
Johnson & Johnson) glucometer. A 20% glucose solution was i.p. injected (2g/kg mouse body 658 
mass). Blood was sampled at 30, 60 and 120 min. Dried blood was quickly removed from the 659 
tail wounds. 660 
Liver perfusion and isolation of hepatic stellate cells and Kupffer cells 661 
The hepatic stellate cells (HSC) and Kupffer cells (KC) were isolated as previously described47. 662 
Particularly, the suprahepatic inferior vena cava was tightened and the inferior vena cava was 663 
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cannulated and perfused with 50 mL Hanks’ balanced salt solutions and then the portal vein 664 
was cut. The perfusion was continued with 50 mL Dulbecco’s modified Eagle medium F/12 665 
(DMEM F/12; GibcoBRL) containing 12.5 mg pronase, followed by 50 mL DMEM F/12 666 
containing 33.3 mg collagenase D (Roche). The liver was removed and agitated in 50 mL 667 
DMEM (GibcoBRL) containing 0.2 mg DNase I, 17 mg pronase and 17 mg collagenase D at 668 
42°C for 10 min. The cell suspension was filtered through a 70 μm cell strainer (Sigma). The 669 
hepatic stellate cells were purified by 8.2% Nycodenz (Accurate Chemical and Scientific 670 
Corporation) and Kupffer cells were isolated from the non-parenchymal cell fraction by CD11b 671 
conjugated magnetic beads (Miltenyi). The purity was confirmed by flow cytometry (KC: ~83%; 672 
HSC: ~85%). 673 
Antibody treatments  674 
Anti-PD-L1 and LALAPG (bind to PD-L1, but cannot inhibit the cell signaling) antibodies were 675 
i.p. injected at 10 mg/kg weekly. Mice were treated for 8 weeks in total. Anti-CD8a antibodies 676 
were i.p. injected weekly (150 μg/mouse). Mice were treated for 6-8 weeks in total. PD-L1 and 677 
control antibodies were kindly provided by I. Mellman (Genentech). 678 
Antibiotic treatment  679 
Ampicillin (1 g/L; Sigma), vancomycin (500 mg/L; MIP Pharma, Blieskastel, Germany), neomycin 680 
sulfate (1 g/L; Sigma) and metronidazole (1 g/L; OTC Pharma GmbH, Kamen, Germany) were 681 
applied via the drinking water as described in Extended Data Fig. 2a. 682 
Adoptive lymphocyte transfer 683 
For adoptive splenocytes transfer, single cell suspensions prepared from spleens were 684 
transferred i.p. with one total spleen injected per mouse. Labelling with 5- (and 6-) 685 
carboxyfluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) was 686 
done according to manufacturer’s protocol. 4×106 CD8+ T cells alone or combined with 10×106 687 
B cells were transferred (equivalent to one spleen). For adoptive lymphocyte transfer (AT), T 688 
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cells were isolated from single cell suspensions of spleens using Pan T cell isolation kit (Miltenyi 689 
Biotec GmbH, Bergisch Gladbach, Germany), and B cells were isolated using Pan B cell 690 
isolation kit. T cells were transferred i.p. alone or with B cells (3-5 × 106 each). The purity of 691 
sorted cells was confirmed by flow cytometry (B cells: ~90%; T cells: ~95%). 692 
Mouse TCR and BCR repertoire analysis 693 
Total RNA was extracted from sorted CD8+ T or B cells with RNeasy Mini Kit (Qiagen, Hilden, 694 
Germany) according to the manufacturer’s instructions. Next-generation sequencing was 695 
performed with an unbiased TCR repertoire analysis technology developed by Repertoire 696 
Genesis Inc. (Osaka, Japan). An unbiased adaptor-ligation PCR was performed according to 697 
the previous reports48. In brief, total RNA was converted to complementary DNA (cDNA) with 698 
Superscript III reverse transcriptase (Invitrogen, Carlsbad, CA)48. Then, double strand (ds)-699 
cDNA was synthesized and an adaptor was ligated to the 5’ end of the ds-cDNA and then cut 700 
with SphI restriction enzyme. For TCRα, PCR was performed with P20EA adaptor primer and 701 
TCR α-chain constant region-specific primer (mCA1). The second PCR was performed with 702 
mCA2 and P20EA primers using the same PCR conditions. For TCRβ, mCB1 and mCB2 703 
primers were used for the first PCR and the second PCR, respectively. For BCR, the following 704 
primers were used: mCM1: GTGTTGGGAAGGTTCTGATA and mCM2: 705 
TTCAGTGTTGTTCTGGTAG (IgM), mBCA1: TAGAGTCATGTTGCACGGAA and mBCA2: 706 
GTTATATCCTTCCCACTCT (IgA). After Tag PCR amplification, index (barcode) sequences 707 
were added by amplification with Nextera XT index kit v2 setA (Illumina, San Diego, CA). 708 
Sequence was done with the Illumina Miseq paired-end platform (2 x 300 bp). Data processing, 709 
assignment, and data aggregation were automatically performed using repertoire analysis 710 
software originally developed by Repertoire Genesis Inc. TCR and BCR (IgM and IgA) 711 
sequences were assigned with a data set of reference sequences from the international 712 
ImMunoGeneTics information system® (IMGT) database (http://www.imgt.org). Nucleotide 713 
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sequences of CDR3 regions ranged from conserved Cysteine at position 104 (Cys104) of IMGT 714 
nomenclature to conserved Phenylalanine at position 118 (Phe118) and the following Glycine 715 
(Gly119) was translated to deduced amino acid sequences. A unique sequence read (USR) was 716 
defined as a sequence read having no identity in V, J and deduced amino acid sequence of 717 
CDR3 with the other sequence reads. The copy number of identical USR were automatically 718 
counted by RG software. TCR and BCR analyses were provided by Repertoire Genesis Inc. 719 
Q-RT-PCR analysis  720 
Total RNA and DNA was extracted using an AllPrep DNA/RNA mini Kit (Qiagen). RNA was 721 
reverse transcribed using a Superscript VILO cDNA synthesis kit (Invitrogen). Quantitative real-722 
time PCR (Q-RT-PCR) was performed as described14. The relative expression levels of target 723 
genes were measured in triplicates and normalized against the level of Rpl32 expression. Fold-724 
difference (as relative mRNA expression) was calculated by the comparative CT method 725 
(2Ct(Rpl32–gene of interest)). Primer obtained from the NIH qPrimerDepot 726 
(http://mouseprimerdepot.nci.nih.gov) are listed as follow: Rpl32, forward 5'-727 
GGGAGCAACAAGAAAACCAA-3', reverse 5'-TTGTGAGCAATCTCAGCACA-3'; Tgfb1, forward 5'-728 
GGAGAGCCCTGGATACCAAC-3', reverse 5'-AAGTTGGCATGGTAGCCCTT-3'; Il21, forward 5'-729 
CCCTTGTCTGTCTGGTAGTCATCTT-3', reverse 5'-GGAGGCGATCTGGCCC-3'; Bcl6, forward 5'-730 
AGTTTCTAGGAAAGGCCGGA-3', reverse 5'-ACTAGCGTGCCGGGTAAACT-3'; Icos, forward 5'-731 
ACAGGGGAGGAGAAGACTGC-3', reverse 5'-CGAGCCATTGATTTCTCCTG-3'; Il33, forward 5'-732 
GAGAAATCACGGCAGAATCA-3', reverse 5'-CTTCTTATTTTGCAAGGCGG-3'; Cxcr4, forward 5'-733 
AGTGACCCTCTGAGGCGTTT-3', reverse 5'-TCCAGACCCCACTTCTTCAG-3'; Cxcr3, forward 5'-734 
AAGTGCCAAAGGCAGAGAAG-3', reverse 5'-CAAAGTCCGAGGCATCTAGC-3'; Cxcl12, forward 5'-735 
TCCTCTTGCTGTCCAGCTCT-3', reverse 5'-GGTAGCTCAGGCTGACTGGT-3'; Cxcl10, forward 5'-736 
CGTCATTTTCTGCCTCATCC-3', reverse 5'-CCTATGGCCCTCATTCTCAC-3'; Cxcl9, forward 5'-737 
GAGGCACGATCCACTACAAA-3', reverse 5'-AGTCCGGATCTAGGCAGGTT-3'; Ccl19, forward 5'-738 
CTTCAGCCTGCTGGTTCTCT-3', reverse 5'-GGAAGGCTTTCACGATGTTC-3'; Cxcl13, forward 5'-739 
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AGGTTGAACTCCACCTCCAG-3', reverse 5'-TTGTGTAATGGGCTTCCAGA-3'; Ccl25, forward 5'-740 
GAAACTGTGGCTTTTTGCCT-3', reverse 5'-TTCCATTTGATCCTGTGCTG-3'; Il7, forward 5'-741 
GCCACATTAAAGACAAAGAAGGT-3', reverse 5'-TGGTTCATTATTCGGGCAAT-3'; Ctgf, forward 5'-742 
CCACCCGAGTTACCAATGAC-3', reverse 5'-GCTTGGCGATTTTAGGTGTC-3'; Ltb, forward 5'-743 
CTTTTCTGAGCCTGTGCTCC-3', reverse 5'-ATCACTGTCCTGGCTGTGC-3'; Col1a1, forward 5'-744 
ACATGTTCAGCTTTGTGGACC-3', reverse 5'-TAGGCCATTGTGTATGCAGC-3'; Afp, forward 5'-745 
GGCGATGGGTGTTTAGAAAG-3', reverse 5'-TCTTTCCACTCCACTTTGGC-3'.  746 
RNA-seq library preparation and sequencing 747 
Total RNA was isolated as described above from 30 livers and 11 HCC nodules as indicated. 748 
Particularly, some of the livers from 6 months old mice were homogenized with Trizol reagent 749 
and extracted with chloroform/isopropanol, followed by the purification using RNeasy Mini Kit 750 
(Qiagen). RNA purity was assessed by Agilent 2100 Bioanalyzer. Sequencing libraries were 751 
prepared from 100 ng of total RNA using the TruSeq Stranded mRNA Library Prep Kit (Illumina) 752 
according to the manufacturer's protocol. Samples were ligated to unique adaptors and 753 
subjected to PCR amplification. Libraries were then validated using the 2100 BioAnalyzer 754 
(Agilent), normalized and pooled for sequencing. RNA-seq libraries prepared from at least three 755 
biological replicates for each group as indicated and were sequenced on the Illumina HiSeq 756 
2500 using barcoded multiplexing and a 100-bp read length. Image analysis and base calling 757 
were done with Illumina HiSeq2500 control software v2.17. The RNA-seq data have been 758 
deposited in NCBI’s Gene Expression Omnibus (GSE90497).  759 
RNA-seq processing and analysis 760 
RNA-seq reads were aligned to the mouse genome (GRCm38/mm10) using STAR (v2.5.2b)49. 761 
Only reads that mapped to a single, unique location in the mouse genome were used for 762 
downstream analysis. Gene expression counts were counted for reads overlapping exons for all 763 
RefSeq transcripts using HOMER50. Differentially expressed genes were determined using 764 
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DESeq251 using thresholds of 5% FDR and a fold change of 1.5 to determine the final lists. 765 
Gene expression profile clustering was performed by first using the DESeq2 rlog variance 766 
stabilization transform to normalize the gene expression values. Heirarchical clustering was 767 
performed using Cluster3.052 and visualized using Java TreeView53. Pathway/Functional 768 
enrichment calculations were performed using Metascape (metascape.org)54. Gene set 769 
enrichment analysis (GSEA) was also performed to identify hallmark genesets55,56. The obtained 770 
results from mouse geneset were compared to previous published human data20,57.  771 
Exome sequencing, processing and analysis 772 
DNA was isolated as described above from 9 spleens and 16 HCC nodules as indicated. Exome 773 
sequencing were performed at the University of California, San Diego, IGM Genomic center 774 
using standard protocols. The exome sequencing data have been deposited in NCBI’s Short 775 
Read Archive (SRA556071, SRP104724).  776 
Exome sequencing data was processed into genetic variants using the Genome Analysis Tool 777 
Kit (GATK). First, exome capture reads were aligned with BWA (version 0.7.15)58 to the mouse 778 
genome (GRCm38/mm10). GATK (version v3.5) was used to process all exome sequencing 779 
data following the recommended best practices workflow59,60. Base recalibration was performed 780 
using the Mouse Genome Project SNP database as a reference for known SNPs61. Variant calls 781 
were made using the GATK HaplotypeCaller while considering the entire dataset together to 782 
maximize sensitivity. Somatic mutations were called by comparing HCC samples to a pool of 783 
splenic controls. Only sites with at least 4 variant allele reads and total coverage of at least 10 784 
reads in both target or control samples were considered. In addition, a minimum of 10% of 785 
target sample reads must contain the variant allele and no more than 2% of control sample 786 
reads could contain the variant allele. Since not all samples had a matching control, each 787 
sample was compared to all background spleen samples to remove any variants that may be 788 
present in any of the splenic control samples. Variants were annotated using snpEff (v4.3)62. 789 
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Coding mutations were defined as variants that directly impacted amino acid changes or splice 790 
sites. Variant visualization was performed using IGV63.  791 
Comparison of gene expression profile and mutation signature between human and 792 
mouse 793 
The direct overlap between genes regulated in human NASH vs. control lean patients64 and the 794 
mouse RNA-seq were found by converting the genes found on the human Affymetrix HuGene 795 
1.1 ST microarray using NCBI Homologene, which maps one-to-one orthologues between 796 
species. Only genes that could be mapped to a unique mouse Entrez Gene ID were considered 797 
(retained ~75% of the total). Homologene was also used to convert Human HCC gene variants 798 
found in the COSMIC database to mouse gene identifiers to compare to mouse mutation 799 
profiles. 800 
Metabolomics analysis 801 
The metabolomic analysis of samples was conducted using reverse phase (RP) ultrahigh 802 
pressure liquid chromatography mass spectrometry (UHPLC MS). The samples were thawed at 803 
RT for approximately 10 min. Each Eppendorf tube with sample was weighted and the sample 804 
weight logged. An aliquot of 0.5 mL of HPLC-grade 80% v:v ethanol:water was added into each 805 
sample tube, and the material was homogenized at 25 Hz for 5 min in Qiagen TissueLyser II 806 
(Qiagen, Hilden, Germany). The samples were allowed to extract for 4 hrs at RT. After 807 
extraction, the tubes were centrifuged for 10 min at 2000 rpm and 400 µL of supernatant from 808 
each tube transferred onto ThermoFisher Scientific (ThermoFisher Scientific, Waltham, MA) 2 809 
mL deep well 96-well plate, dried down and then re-suspended in 300 μL of 50% v:v 810 
ethanol:water. The plates were sealed, sonicated for 10 min, centrifuged at 2000 rpm for 10 min 811 
and a 50 μL aliquote of each sample transferred onto Falcon 96 wells MS plate, which was then 812 
immediately sealed with sealing film. The MS plates were centrifuged at 2000 rpm for 10 min 813 
and stored at 2 °C until analysis. Blanks of resuspension solvent as well as the solvent that went 814 
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through the extraction procedure steps (sample extraction blank) were included with each batch. 815 
Also, quality control was included at the beginning and end of each sample batch to control 816 
instrument performance.  817 
The HPLC MS analysis was performed on Dionex UltiMate 3000 ThermoFisher Scientific 818 
UHPLC system (ThermoFisher Scientific, Waltham, MA) coupled to Bruker impact HD 819 
quadrupole time-of-flight (QTOF) mass spectrometer (Bruker, Billerica, MA). The 820 
chromatographic separation was carried out on Kinetex C18 1.7 μm, 100Å UHPLC column (50 821 
mm x 2.1 mm) (Phenomenex, Torrance, CA), held at 40 ºC during analysis. 5 μL of sample was 822 
injected. Mobile phase A was water, mobile phase B was acetonitrile, both with added 0.1% v:v 823 
formic acid. The solvent gradient table was set as follows: 2% B, increased to 10% B over 0.2 824 
min, then to 100% B at 12 min, held at 100% B for 1.5 min, decreased back to 2% B in 0.5 min 825 
followed by washout cycle and equilibration for a total analysis time of 15 min. The scanned m/z 826 
range was 80-2000 Th; capillary voltage 4500 V; nebulizer gas pressure 2 bar, drying gas flow 827 
rate 9 L/min and temperature 200 °C. The full MS scan was followed by MS/MS fragmentation 828 
of 7 most abundant ions in the spectrum. For MS/MS, the collision cell collision energy was set 829 
at 3 eV and the collision energy was stepped 50%, 75%, 150% and 200%. The scan rate was 3 830 
Hz. A HP-921 lock mass compound was infused during the analysis to carry out post-831 
processing mass correction.  832 
The collected LC/MS raw data files were converted to mzXML format and feature detection was 833 
carried out with the OpenMS 2.0 software65. The alignment window was set at 0.5 min, noise 834 
threshold at 1000 counts, chromatographic peak FWHM at 20 and mass error at 30 ppm 835 
(https://github.com/rsilvabioinfo/openms_snakemake). All of the peaks that were present in any 836 
of the blanks with S/N below 3:1 were removed from the final feature table. The extracted 837 
feature table was parsed into tables corresponding to different experimental categories which 838 
then were used as input for the MetaboAnalyst software66. The feature tables were filtered with 839 
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Interquantile range (IQR) to remove outliers, the data normalized by sum total of peak 840 
intensities and autoscaled (mean centering and dividing by standard deviation for each feature). 841 
Principal component analysis (PCA) and Partial least squares Discriminant Analysis (PLS-DA) 842 
were used to explore and visualize variance within data and differences among experimental 843 
categories. The HFD-fed MUP-uPA strains were found to be concordant between two different 844 
age groups, 6 and 11 months in either the 16S rRNA sequencing or the metabolomics. For 16S 845 
sequencing, the effect of animal age on microbiota was minimal (P=0.021, pseudo F-846 
statistic=1.66) in comparison to immune status (P=0.001, F-statistic=5.19) by PERMANOVA 847 
(999 permutations) on the unweighted UniFrac distance matrix and age was not significant by 848 
PERMANOVA on the weighted UniFrac distance matrix (P=0.095, pseudo F-statistic=1.766). 849 
Similarly, in metabolomics analysis the effect of age (PLS-DA 10-fold cross validation Q2 value 850 
of 0.477) was minor compared to the immune status (PLS-DA 10-fold cross validation Q2 value 851 
of 0.926 for WT vs Iga-/- and 0.934 for WT and Cd8a-/- correspondingly). Therefore, for some 852 
analyses, data from both time points were pooled to increase the sample numbers. All of the 853 
raw data are publicly available at the UCSD Center for Computational Mass Spectrometry (the 854 
dataset ID MassIVE MSV000080918).  855 
Bacterial genomic DNA extraction and 16S rRNA gene amplification and sequencing 856 
For the 16S rRNA analyses, feces were taken from indicated mice strains. The analyzed 857 
genotypes (Cd8a-/-, Iga-/-, μMT-/-, Rag1-/-, Pigr-/-, IgHel/MD4) were housed separately. Out of 32 858 
MUP-uPA/Cd8a-/- mice, five were cohoused with Cd8a+/-. For the MUP-uPA group, some MUP-859 
uPA negative control mice were co-housed with MUP-uPA positive groups. DNA was extracted 860 
using the MagAttract PowerSoil DNA KF Kit (Qiagen, Germany) following protocols 861 
benchmarked through the Earth Microbiome Project (http://www.earthmicrobiome.org/protocols-862 
and-standards/dna-extractionprotocol/). The V4 of the 16S rRNA gene was then amplified with 863 
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PCR again following protocols benchmarked through the Earth Microbiome Project 864 
(http://www.earthmicrobiome.org/protocols-and-standards/16s/)67. This approach facilitates the 865 
capture of most of the bacteria present in a sample due to the ubiquitous nature of the 16S 866 
rRNA gene and the “universal” V4 primer. The V4 region recapitulates the full-length 16S rRNA 867 
gene at approximately genus level resolution. Barcoded amplicons were then sequenced on an 868 
Illumina MiSeq using the 2 x 150 bp protocol at the Institute for Genomic Medicine at UC San 869 
Diego. The data are publically available at the European Bioinformatics Institute (EBI; 870 
ERP022642).   871 
16S rRNA sequencing data analysis 872 
The data were deposited and prepared in Qiita (http://qiita.microbio.me; study id: 10856). Raw 873 
sequences were de-multiplexed using QIIME 1.9.168 following the default parameters available 874 
in Qiita. De-multiplexed sequences were then trimmed to 150 bp and denoised using Deblur 875 
(accepted for publication in mSystems). Since some downstream analyses require a 876 
phylogenetic tree, we used SEPP69 to generate this tree (see 877 
https://github.com/smirarab/sepp/tree/master/sepp-package) by inserting the V4 fragment 878 
sequences resulting from Deblur into the Greengenes tree70. Taxonomy was assigned to the 879 
sequences using the taxonomy present on the internal nodes of the already annotated 880 
Greengenes tree, and this taxonomy information was added to the biom-format observation 881 
matrix71 containing unique sequences and their abundances in each sample. The samples 882 
included in downstream analysis had at least 4500 sequences per sample. Alpha diversity 883 
statistical analyses were performed using a non-parametric t-test with Monte Carlo permutations 884 
to calculate the P value72. The Unweighted UniFrac Beta diversity distances between samples 885 
were computed on a rarefied table of 4500 sequences per sample73. Principal Components 886 
Analysis (PCoA) was applied to the resulting distance matrix and plots were generated using 887 
the Emperor software74. To analyze the significance of sample groupings, PERMANOVA 888 
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(nonparametric, 999 permutations) was performed on the UniFrac distance matrices using 889 
QIIME 1.9.1. Stacked barplots of relative bacterial abundance were created using Matplotlib and 890 
heat maps were created with Seaborn. Significant differences in deblur sequences between 891 
groups was assessed using the scikit-bio implementation of ANCOM75 with a Bonferroni 892 
correction for multiple comparisons  893 
(http://scikit-bio.org/docs/0.4.2/generated/generated/skbio.stats.composition.ancom.html).  894 
For the microbiome PCoA plots, the samples displayed in each figure are indicated in the 895 
publicly available sample information file in Qiita study ID 10856 (https://qiita.ucsd.edu/). Each 896 
PCoA plot figure has a column in the sample information file (labeled “Figure#_Extended_Data”) 897 
which indicates whether that sample was included in the plot with a “True” or “False” value and 898 
a column describing the subsequent grouping. This file can be downloaded and used in 899 
conjunction with the sequencing data to recreate the plots. 900 
Analysis of bacteria by Q-RT-PCR quantification of 16S rRNA-encoding DNA 901 
For analyses of gut-bacteria content, feces total DNAs extracts were prepared using Powersoil® 902 
DNA isolation kit. The abundance of total feces bacteria was measured by Q-RT-PCR based on 903 
a SYBR Green Assay using a universal bacterial 16S rRNA-encoding DNA primers (16S-V6-904 
784F: AGGATTAGATACCCTGGTA; 16S-V6-1061R: CRRCACGAGCTGACGAC). The primers 905 
were first used to amplify 16S rRNA gene fragment from pooled DNA extracts. The DNA 906 
fragment was purified and quantified. As reference for quantification, standard curves with serial 907 
dilutions of purified 16S rRNA gene fragment were generated for each run.  908 
Data availability  909 
The RNA-seq (GSE90497; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE90497), 910 
exome sequencing (SRA556071, SRP104724; 911 
https://www.ncbi.nlm.nih.gov/sra/?term=SRA556071) and 16S rRNA sequencing (ERP022642; 912 
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http://www.ebi.ac.uk/ena/data/view/PRJEB20486) data are available in NCBI’s Gene 913 
Expression Omnibus database, NCBI’s Short Read Archive database and European 914 
Bioinformatics Institute, respectively. Samples displayed in the microbiome PCoA plots are 915 
indicated in the publicly available sample information in Qiita study ID 10856 916 
(https://qiita.ucsd.edu/). The metabolomics raw data are publicly available at the UCSD Center 917 
for Computational Mass Spectrometry (the dataset ID MassIVE MSV000080918): 918 
ftp://massive.ucsd.edu/MSV000080918. 919 
The raw and processed feature tables used in preparation of the “Metabolome” panels in the 920 
“Extended Data Figure 7” (k), (l), (m), (n) and (q) panels as well as the data processing reports 921 
generated by the Metaboanalyst are included along with the raw data (the dataset ID MassIVE 922 
MSV000080558) at: http://massive.ucsd.edu/MSV000080558. 923 
Source Data are available in the online version of the paper. All other data are available from 924 
the corresponding authors upon reasonable request. 925 
Code availability 926 
The microbiome data analysis was primarily done using Qiita & QIIME, and the custom code 927 
used for taxonomic assignment from the phylogenetic tree generated with SEPP 928 
(https://github.com/smirarab/sepp/blob/master/sepp-package/README.md) is available online 929 
at Github (https://github.com/knightlab-analyses/shalapour-nature-iga-liver-930 
cancer/blob/master/assignTaxa.ipynb). Scripts used to parse, filter, and organize data and 931 
results for RNA-seq and DNA exome sequencing are available upon request. 932 
Statistical analysis and reproducibility  933 
Data are presented either as means ± SEM or medians of continuous values and were analyzed 934 
by two-sided Students’ t-test or Mann-Whitney test for comparison of two groups, respectively. 935 
Two-way ANOVA was used to compare three or more groups in mouse data analyses. One-way 936 
ANOVA or Kruskal-Wallis test was used to compare three or more groups in human data 937 
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analyses. Bonferroni’s or Dunn’s multiple comparison test was applied to compare all pairs of 938 
groups. D'Agostino & Pearson test and/or Shapiro-Wilk test were used to test the normality of 939 
sample distribution. Fisher's exact Chi-square t test was used to calculate statistical significance 940 
of categorical values between groups. Two tailed P values of ≤ 0.05 were considered significant. 941 
Linear regression was used to determine the correlation between two different variables. 942 
GraphPad PRISM software was used for statistical analyses. Unpaired t test was used to 943 
determine the power using GraphPad StatMate software.  944 
Representative example of power calculations (α=0.05, two-tailed) for important groups are 945 
shown as follow. 1. MUP-uPA model: MUP-uPA+HFD (24) vs MUP-uPA +NC (8)≈99%; MUP-946 
uPA+HFD (24) vs MUP-uPA+HFD+Abx (6)≈85%; MUP-uPA+HFD (24) vs MUP-uPA/Iga-/-+HFD 947 
(26)≈95%; MUP-uPA+HFD (24) vs MUP-uPA/μMT -/-+HFD (9)≈75%; MUP-uPA+HFD (24) vs 948 
MUP-uPA/Cd8a-/-+HFD (31)≈85%. 2. STAM model: WT-FVB (13) vs FVB/Iga-/- (15)>99%; WT-949 
FVB (13) vs FVB/JH-/- (7)>99%; WT-FVB (13) vs FVB/Tgfbr2△B (4)≈95%; WT-FVB (13) vs 950 
FVB/Cd8a-/- (19)>99%; WT-BL6 (17) vs BL6/μMT-/- (3)≈75%; WT-BL6 (17) vs BL6/Pigr-/- 951 
(9)≈99%; WT-BL6 (17) vs BL6/Cd8a-/- (5)≈99%. 3. CD8 depletion: STAM-FVB: Iga-/- (15) vs 952 
Iga-/-+αCD8 (3)>99%; MUP-uPA+HFD: Iga-/- (3) vs Iga-/-+αCD8 (3)≈70%. 4. Adoptive 953 
lymphocyte transfer in MUP-uPA+HFD model: Rag1-/- (7) vs Rag1-/- (T cells) (4)≈90%; Rag1-/- 954 
(T+B cells) (4) vs Rag1-/- (T cells) (4)≈85%. 5. αPD-L1 treatment in MUP-uPA+HFD model: ctrl 955 
(8) vs αPD-L1 (7)≈80%; LALAPG (7) vs αPD-L1 (7)≈99%. 956 
The number of analyzed and treated mice are shown in Supplementary Table 1 and 2, with a 957 
total mouse number of 813 from 74 single experiments. Experiments were repeated 958 
independently at least 2-3 time with similar results. 959 
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Extended Data Figure legends 1070 
Extended Data Figure 1 | NASH-induced accumulation of IgA+ plasmocytes in human liver. (a) 1071 
Serum IgA levels of NAFLD/NASH patients (Newcastle cohort; n=502) were analyzed, and compared with 1072 
clinical data. (b) Serum was collected from a second cohort of NAFLD/NASH patients (San Diego cohort; 1073 
n=96), whose degree of liver fibrosis was measured by MRI and classified as grades 0 (n=51), 1-2 (n=33) 1074 
and 3-4 (n=12). Serum concentrations of IgA, IgG and IgM were determined by ELISA and plotted against 1075 
the fibrosis grade. (c) Single cell suspensions were prepared from liver biopsies taken from NASH 1076 
patients (n=4) with fibrosis, stained with antibodies to IgA, CD19 and PD-L1 and analyzed by flow 1077 
cytometry. Blood collected from 3 healthy donors (used as a surrogate for liver biopsies which cannot be 1078 
obtained from such individuals, HD), stained with antibodies, as indicated. Shown are representative 1079 
scatter plots from two patients and two healthy donors. Shown are bar graphs compiling data from all 1080 
samples and depicting PD-L1 expression by IgA+ cells. (d) Single cell suspensions were prepared from 1081 
liver biopsies as above (n=3 per group), and were stained with antibodies to CD4, CD8, Tim-3 and PD-1. 1082 
Shown are representative data from one patient and one HD with bar graphs compiling results obtained 1083 
from three patients and depicting frequencies of PD-1+CD8+ T cells. Chi-Squared test (a) and two-sided 1084 
T-test (Means±SEM; panel a-d) were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. 1085 
not significant.  1086 
Extended Data Figure 2 | Experimental scheme and comparison of different NASH, HCC and liver 1087 
damage mouse models. (a) In the HFD-fed MUP-uPA model, MUP-uPA, MUP-uPA/Iga-/-, MUP-1088 
uPA/μMT-/-, MUP-uPA/Rag1-/- and MUP-uPA/Cd8a-/- male mice were kept on normal chow (NC) or placed 1089 
on high fat diet (HFD) starting at 8 weeks of age. Mice were analyzed for NASH-related immune 1090 
parameters and pathology at 6 months of age and for HCC-related parameters at 11 months of age 1091 
(n=543 mice analyzed in 50 experiments). Mice were treated with a cocktail of broad spectrum antibiotics 1092 
(Abx) from 3 to 6 m or 6 to 11 m to determine microbe impact on NASH and HCC, respectively. Mice 1093 
were also subjected to weekly anti-PD-L1 or anti-CD8 antibody injections starting at 9m of age for a total 1094 
of 8 or 6 weeks before being evaluated for HCC. In the STAM model, male mice of indicated genotype 1095 
were subcutaneously injected with 200 μg streptozotocin (STZ) 2 days after birth and fed with HFD after 4 1096 
weeks of age. Tumor multiplicity, immune parameters and pathology were determined when the mice 1097 
were 25 or 20 weeks of age in either the BL6 or FVB backgrounds, respectively (n=123 mice analyzed in 1098 
15 experiments). STAM-Iga-/- mice were also subjected to weekly anti-CD8 antibody injections for a total 1099 
of 5 weeks before being evaluated for HCC. In the MCD HFD-fed model, mice were kept on a methionine 1100 
and choline deficient (MCD) diet with 60 kcal% fat, for 4 weeks (n=65 analyzed in 3 experiments). In the 1101 
CCl4 model, mice were injected i.p. with CCl4 bi-weekly for 8 weeks (n=82 analyzed in 6 experiments). (b) 1102 
Paraffin-embedded and frozen mouse liver sections (n=3-9 per group as indicated) were stained with 1103 
H&E to determine liver histology (magnification bar: 100 μm), Sirius Red (SR) to determine collagen fiber 1104 
deposition (magnification bar: 100 μm) or Oil red O (ORO) to determine lipid droplet accumulation 1105 
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(magnification bar: 50 μm). (c) Paraffin-embedded human liver sections from non-alcoholic steatohepatitis 1106 
(NASH) and alcoholic steatohepatitis (ASH) patients were stained with Sirius Red to determine collagen 1107 
fiber deposition (n=5 per group with one representative shown; magnification bar: 250 μm). The data were 1108 
validated in at least 2-3 experiments. (d) Spleen content of IgA+ cells (absolute cell number per spleen) in 1109 
different mouse strains and treatment groups (n=11, 6, 8, 13, 11, 9). (e,f) Indicated mice were placed on 1110 
the different models described in (a). At the endpoints, mouse body weights were measured (e) (n= 6, 5, 1111 
8, 10, 3, 10, 11, 31, 15, 6, 9) and sera were analyzed for ALT (f) (n= 6, 5, 6, 5, 3, 13, 3, 10, 8, 3, 6), an 1112 
indicator of liver damage. (g,h) Collagen deposition and lipid droplets were quantified using image 1113 
analysis software and data points for individual mice are shown (g: n=11, 6, 3, 9, 3, 8, 4, 6, 5; h: n=6, 5, 1114 
3, 3, 3, 5, 4, 8, 4, 3, 6). (i) Total RNA was extracted from livers of indicated mice and analyzed by Q-RT-1115 
PCR using primers for Tgfb1 (n=6, 5, 3, 7, 7, 6, 6). (j) Hepatic stellate cells (HSC), CD11b+ Kupffer cells 1116 
(KC) and CD11b- non-parenchymal cells (NPC) from the indicated mice were isolated from livers. Total 1117 
RNA was extracted from the above cells and analyzed for Tgfb1 mRNA expression (n=3-5). (k,l) CD4+ T 1118 
cells were sorted from livers of NC- and HFD-fed WT or HFD-fed MUP-uPA mice using CD4, CD8, CD45 1119 
and CD3 antibodies. RNA was extracted and analyzed by Q-RT-PCR using primers for Il21, Bcl6 and Icos 1120 
(n=4-7 as indicated). (m) Total RNA was extracted from livers of indicated mice and analyzed by Q-RT-1121 
PCR for Il33 (n=4, 5, 3, 7, 8, 6, 6). (n,o) Total RNA was extracted from livers of indicated mice at 6m 1122 
(n=29 mice in total, with 3-8 mice per group as indicated) (n) or tumors of indicated mice at 11m of age 1123 
(n=7,9) (o), and analyzed by Q-RT-PCR for chemokine and cytokine mRNA. The heat map in (n) depicts 1124 
the differential expression of immune-regulatory genes. Two-sided T-test (Means±SEM; panel g-m) and 1125 
Mann-Whitney test (Median; panel d-f,o) were used to determine significance. *P<0.05; **P<0.01; 1126 
***P<0.001; n.s. not significant. N-values for each group are shown either in individual panels or in 1127 
legends for each group from left to right accordingly. 1128 
Extended Data Figure 3 | IgA characterization in the indicated tissue of STAM and MUP-uPA mice. 1129 
(a-e) Single splenocyte or liver cell suspensions from tumor (HCC)-bearing mice (STAM-B6) were stained 1130 
with CD45, CD19, IgA, CD138, B220 and PD-L1, and FVD-eF780 was used to exclude dead cells. (a) 1131 
Shown are the gating strategies for splenocytes and liver lymphocytes: lymphocyte gate, dead cell 1132 
exclusion, doublets exclusion and CD45+ population gate. (b) Flow cytometry analysis of IgA and CD19 1133 
expression of indicated strains, gated on the CD45+ population. Spleen or liver from Iga-/- mice were used 1134 
to set up the gating for the populations. Tgfbr2ΔB and Pdl1/2-/- mice clearly showed less IgA+ cells 1135 
compared to WT mice. (c-e) IgA subpopulations were gated as indicated and analyzed for CD138, B220 1136 
and PD-L1 expression. IgA subpopulations were gated based on CD19 expression, in indicated strains, 1137 
and the IgA+CD19+, IgA+CD19-/low/int and IgA-CD19+ subpopulations were further analyzed for their B220 1138 
and CD138 expression. The decision for CD19 and CD138 levels were also based on their MFI (red). The 1139 
analyses showed two main populations: 1) IgA+CD19+B220+CD138low/- and 2) IgA+CD19-/intB220-1140 
CD138+/hi. These two populations and the IgA-CD19+ populations were further analyzed for their ability to 1141 
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express PD-L1 (% and MFI). (f-j) Single cell suspensions were prepared from the spleen, liver or intestine 1142 
of MUP-uPA mice kept on normal chow (NC) or high fat diet (HFD) were stained with CD45, CD19, IgA, 1143 
B220, CD138, CD11b, MHCII, PD-L1 and CD5, and analyzed by flow cytometry. (f) The B220 and CD138 1144 
expression in total IgA+ cells (CD19+ and CD19- population) confirmed that most of the IgA+ cells in 1145 
spleen and liver of HFD-fed MUP-uPA mice are CD138+ cells. (g,h) IgA subpopulations in liver (g) and 1146 
Spleen (h) were gated as indicated and analyzed for CD138, B220 and MHCII expression. (i) Shown are 1147 
the representative dot-plots gated on IgA+ cells, showing that most of the IgA+ cells are not CD11b+. (j) 1148 
Shown are the PD-L1 and CD5 expression of IgA+ cells in spleen, liver and intestine. 1149 
Extended Data Figure 4 | (a) Single cell suspensions were prepared from the livers of tumor-bearing 1150 
mice (STAM-B6) as indicated. Shown are the PD-L1 and IgA staining in indicated strains. Spleen or liver 1151 
from Iga-/- and pdl1/2-/- mice were used as control for IgA and PD-L1 staining. (b) Liver single cell 1152 
suspension of MUP-uPA mice and indicated strains were stained for CD45, IgA and PD-L1. Percentages 1153 
of liver PD-L1+ cells in CD45+IgA- (labeled: CD45+) or IgA+ cell populations from the indicated strains are 1154 
shown (n=8, 6, 6, 7, 6, 6, 18, 16, 11, 12). (c) Percentages of liver PD-L1+CD45+ cells are shown in 1155 
indicated strains (n=5, 6, 6, 16, 10). The data were validated in at least 3 different experiments. (d-e) 1156 
CD138+ cells were divided into IgA+ and IgA- populations and analyzed for PD-L1 expression. (d) Shown 1157 
is the mean fluorescence intensity (MFI) of PD-L1 expression for CD138+ cells from spleen (gated on 1158 
either CD138+IgA- or CD138+IgA+ cells). (e) MFI of PD-L1 expression is shown for CD138+ plasmocytes 1159 
from livers of 19 mice (gated on either CD138+IgA- or CD138+IgA+ plasma cells). (f) Percentages of 1160 
intestinal IgA+ cells in MUP-uPA mice kept on NC or HFD (n=6, 13; left). Percentages of PD-L1+IgA+ cells 1161 
in intestine and liver are included for comparison (n=7, 8; right). (g) Percentages of liver IgA+ cells are 1162 
shown in indicated strains kept on HFD at the age of 3 m (n=9, 7). (h) Percentages of PD-L1+ cells are 1163 
shown gated on CD45+CD19-IgA- cells in the indicated strains (n=3, 4, 5). The data were validated at 1164 
least in 2-3 experiments. Two-sided Mann-Whitney test (Median; panel b,c,e-h) were used to determine 1165 
significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not significant. N-values for each group in each panel 1166 
are provided from left to right accordingly.  1167 
Extended Data Figure 5 | CD8+ T cells and IgA+ plasmocytes are only marginal players in the MUP-1168 
uPA NASH model. (a) Comparison of weight gain by different strains of mice kept either on NC or HFD. 1169 
Mice were continuously monitored from 8 to 46 weeks, and 20 data points were used to analyze weight 1170 
gain, with at least 11 to 52 mice per time point (see online Source Data), and 5 BL6 mice on NC were 1171 
used as controls. (b-e) Sera, blood and liver samples were collected from mice of the indicated strains 1172 
and ages. Serum and blood samples were analyzed for ALT (n=13, 13, 16) (b), glucose tolerance test 1173 
(n=3-6 as indicated) (c), cholesterol (n=5, 8, 9, 7) (d), or triglycerides (n=5, 8, 9, 7) (e, left). Liver extracts 1174 
were analyzed for triglycerides (e, right) (n=5, 9, 11, 7). (f) Total RNA was extracted from livers of 1175 
indicated mice and analyzed by Q-RT-PCR for Col1a1 mRNA (n=4, 4, 3, 6, 4, 8). (g-i) Paraffin-embedded 1176 
and frozen liver sections were stained with H&E to determine liver histology (magnification bar: 100 μm 1177 
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except 50 μm in the second panel of g), Sirius Red (SR) to determine collagen fiber deposition 1178 
(magnification bar: 100 μm) or Oil red O (ORO) to determine lipid droplet accumulation (magnification bar: 1179 
50 μm) in the indicated strains and models (Extended Data Fig. 2a). Representative images are shown 1180 
and were validated at least 2-3 times. Collagen deposition and lipid droplets were quantified using image 1181 
analysis software and data points for individual mice are shown on the right for the MUP-uPA (g) (SR: 1182 
n=9, 14, 10; ORO: 5, 6, 3), and MCD (h) (n=3 per group) models. (i) Shown are representative SR 1183 
staining for the CCl4 model (n=4-5 mice per group). (j) Total RNA from livers of 6m old mice of the 1184 
indicated genotypes was subjected to RNA-seq analysis. Shown is the hierarchical clustering of gene 1185 
expression profiles comparing HFD- and NC-fed mouse liver samples. The top 3 enriched 1186 
pathways/functional categories from Metascape were reported for major clusters of genes. (k) Total RNA 1187 
from livers of indicated mice was analyzed by Q-RT-PCR for α fetoprotein (Afp) mRNA (n=5, 5, 6, 5, 6, 6, 1188 
5, 8, 6, 6). The data were validated at least in 2-3 experiments (see Supplementary Table 1-2). Two-way 1189 
ANOVA (Means±SEM; panel a,c), two-sided T-test (Means±SEM; panel f-h,k) and Mann-Whitney test 1190 
(Median; panel b,d,e,g,h) were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not 1191 
significant. N-values for each group are shown either in individual panels or in legends for each group 1192 
from left to right accordingly. 1193 
Extended Data Figure 6 | IgA ablation inhibits, while CD8 deficiency accelerates HCC 1194 
development. (a,b) Total DNA was extracted from HCC nodules of 11m old mice (n=16) of the indicated 1195 
genotypes with or without αPD-L1 treatment, and subjected to Exome sequencing. Shown are the 1196 
number of point mutations identified per sample (a) and mutational signatures (b). Horizontal axis shows 1197 
96-substitution patterns with substitution subtypes on top, and vertical axis indicates probability of each 1198 
pattern in b. (c) Top 20 hallmark gene sets sorted by normalized enrichment score (NES) are shown to 1199 
depict HCC progression in MUP-uPA and MUP-uPA/Iga-/- mice by GSEA analysis. Immune-related gene 1200 
sets are colored blue. The gene sets previously described20,57 for human HCC are marked (*red). (d) 1201 
Total RNA was extracted from livers of 6m old mice and from HCC nodules of 11m old mice of the 1202 
indicated genotypes and subjected to RNA-seq analysis. Hierarchical clustering of gene expression 1203 
profiles comparing HCC and non-HCC mouse samples according to the RNA-seq. The top 3 enriched 1204 
pathways/functional categories from Metascape are reported for major clusters of genes. (e) 1205 
Representative images of liver histology at different time points and indicated strains are shown with 1206 
detailed n-values. Magnification bars: 100 μm (3m), 250 μm (6,11m). (f) Total tumor numbers in 3m old 1207 
MUP-uPA mice (n=11, 7, 8). (g) Shown is a heat map depicting differential expression of 17 liver-specific 1208 
genes and 33 HCC-related genes in indicated strains, illustrating the upregulation of some HCC-related 1209 
genes in MUP-uPA/Cd8a-/- livers at 6m of age (total mice number: 29; n=3-4 per group). (h-j) BL6 mice of 1210 
the indicated phenotype were subjected to the STAM protocol and their tumor volumes (n=14, 6, 6, 4, 3, 1211 
9, 3) (h) and histopathology (i,j) were evaluated at 25 weeks of age. The data were validated at least in 2-1212 
3 experiments. Paraffin-embedded and frozen liver sections from these mice were stained with H&E, 1213 
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Sirius Red (SR) or Oil red O (ORO), as indicated. Shown are typical images of tumor-containing and 1214 
tumor-free areas, the borders between which are marked by the black lines. Magnification bars; H&E: 100 1215 
μm; SR: 100, 250 or 500 μm. ORO: 50 μm. ORO positive areas were quantitated and shown on the right. 1216 
The SR stained areas for each mouse were calculated by image analysis of the whole tissue scan and 1217 
normalized to the H&E stain (n=3-4 per group). (k) Tumor volumes are shown for STAM-WT (n=10), 1218 
STAM-Iga-/- (n=13) and STAM-Iga-/- after CD8 depletion (n=3). (l) MUP-uPA/Iga-/--HFD mice were injected 1219 
weekly with anti-CD8 for 6 weeks and tumor multiplicity was determined (n=3). (k,l) CD8 depletion 1220 
experiments were repeated using two different HCC models (MUP and STAM). (m) Shown is a heat map 1221 
depicting the differential expression of 59 genes involved in allograft rejection, IFNγ response and 1222 
inflammation (total mouse number: 41; 6m: n=3 and 11m: 3-4 per group). (n,o) Paraffin-embedded and 1223 
frozen liver sections from 11m old mice (n) and adoptively transferred mice (o) were stained with H&E, 1224 
SR or ORO as indicated and analyzed (SR: n=9, 16, 14, 6; ORO: n=8, 5, 5, 8 for panel n). Shown are 1225 
typical images of tumor-containing and tumor-free areas, the borders between which are marked by the 1226 
black lines. (p) Liver cells from MUP-uPA/Rag1-/- mice 1 week after being adoptively transferred with 1227 
CFSE-labeled T cells with or without B cells as indicated (n=3 in each group) were stained and analyzed 1228 
by flow cytometry. Shown are the percentage of CD8+ T cells amongst CD45+ cells (left), and histogram 1229 
of proliferating CFSE-labeled T cells with the corresponding MFI (right). (q) Liver sections for MUP-1230 
uPA/Rag1-/- and the corresponding adoptive lymphocyte transfer mice (4 weeks after AT) were stained 1231 
with αSMA, IgA, CD3 and CD8 antibodies, counterstained with DAPI and examined by fluorescent 1232 
microscopy (magnification bars: 50 μm). For CD3/CD8 staining, images with higher magnification are 1233 
shown (magnification bars: 20 μm). Single cell suspensions were prepared from the corresponding liver, 1234 
stained with antibodies to CD45, IgA, CD19, B220, CD8 and CD4, and analyzed by flow cytometry. 1235 
Shown are representative scatter plots. MUP;Rag1-/- mouse livers have been used for validation of CD4, 1236 
CD8, IgA and CD19, both for Flow cytometry and immunofluorescence analyses. The data were validated 1237 
at least in 2 experiments. (r) STAM-BL6 mice of indicated phenotypes were analyzed for IgA serum 1238 
amounts by ELISA (n=11, 4, 4, 4, 4). (s) Shown is the absolute IgA+ cell number in livers of indicated 1239 
STAM-BL6 mice (n=13, 4, 4, 9, 8). Each dot represents a mouse. Two-sided T-test (Means±SEM; panel 1240 
f,j,l,n,r) and Mann-Whitney test (Median; panel h,k,n,s) were used to determine significance. *P<0.05; 1241 
**P<0.01; ***P<0.001; n.s. not significant. N-values for each group are shown either in individual panels 1242 
or in legends for each group from left to right accordingly. 1243 
Extended Data Figure 7 | Gut microbes promote HCC development. Microbial translocation does 1244 
not account for the anti-tumorigenic effect of IgA ablation. (a-j) MUP-uPA and MUP-uPA/Iga-/- mice 1245 
were placed on HFD and treated with broad spectrum antibiotics (Abx) as described in Extended Data 1246 
Fig. 2a, from 3 to 6 (all panels except right part of panel b and panel d,h,i) or 6 to 11 (right part of panel 1247 
b, and panels d,h,i) m of age. At the end of the treatments, the stool contents of the corresponding mice 1248 
were subjected to eubacterial 16S rRNA encoding DNA sequencing. (a) Principal Coordinate Analysis 1249 
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(PCoA) plot of microbiome data using unweighted UniFrac distances, antibiotic treatment was significant 1250 
by PERMANOVA (pseudo-F statistic=105.5, P=0.001) (Left: n=181, 27 as indicated; right: n=6, 3, 6, 3). 1251 
Mouse weight (6m: n=5, 6, 13, 7; 11m: n=8, 6, 5, 7) (b) and circulating ALT (n=12, 5, 12, 6) (e) were 1252 
measured. (c,d) Paraffin-embedded and frozen liver sections from the above mice were stained with 1253 
H&E, Sirius Red (SR) or Oil red O (ORO), and were analyzed for collagen deposition and lipid droplets as 1254 
indicated. Magnification bars: 50 μm for ORO, and 100 μm for H&E and SR (SR: n=9, 6, 14, 7 for c and 4, 1255 
4, 5 for d; ORO: n=5, 3, 6, 3 mice). The data were validated at least in 2-3 experiments. (f-h, j) Liver cell 1256 
suspensions were stained with antibodies as indicated, and analyzed by flow cytometry. Each dot 1257 
represents one mouse. Shown are percentages of: CD8+ cells in total cells (n=11, 5, 9, 7), CD8+CD44+ 1258 
(n=10, 4, 11, 6) or CD8+IFNγ+CD107a+TNF+ (n=8, 6, 9, 7) cells in CD8+ T cells (f), CD19+B220+ cells in 1259 
CD45+ cells (n=9, 6, 11, 7) (g), IgA+ cells in CD45+ cells (n= 6, 6, 6, 3, 6, 6) (h), CD4+ cells in CD45+ cells 1260 
(n=9, 6, 11, 7) or IL-17+ cells in CD4+ T cells (n= 9, 6, 10, 6) (j). (i) MUP-uPA mice placed on HFD and 1261 
treated with Abx were analyzed for serum IgA by ELISA (n=4, 8, 5, 6, 5, 5). Note that flow cytometry data 1262 
of MUP-uPA and MUP-uPA/Iga-/- mice, that were not treated with Abx (ctrl mice), are also shown in Fig. 3 1263 
and Extended Data Fig. 8q-y. The data were validated at least in 2-3 experiments. (k-r) Effects of HFD 1264 
and immunological background on mouse intestinal microbiomes and metabolomes (total mouse number 1265 
n=288). Each dot represent one mouse. (k) The most pronounced differences are engendered by HFD 1266 
compared to NC, left to right: Principal Coordinate Analysis (PCoA) plot of microbiome data using 1267 
unweighted UniFrac distances (PERMANOVA, pseudo-F statistic=46, P=0.001 comparing diet); barchart 1268 
of relative abundances of bacterial phyla; Principal Component Analysis (PCA) plot of metabolome. (k,l) 1269 
Subsequent effect of immune status for the MUP-uPA HFD-fed mice: WT, Iga-/-, Cd8a-/-, μMT-/- and Rag1-1270 
/- groups. (l) Left to right: PCoA plot of microbiome data using unweighted UniFrac distances 1271 
(PERMANOVA, pseudo-F statistic=4.37, P=0.001 comparing immune status); PCA plot of metabolome, 1272 
Partial least squares Discriminant Analysis (PLS-DA) plot (the 10-fold cross validation Q2 value was 1273 
0.817) plot of metabolome. Large differences between categories are evident. Subsequent juxtaposition 1274 
of the (m) MUP and MUP;Iga-/-: PCoA of plot of microbiome using unweighted UniFrac distances 1275 
(PERMANOVA, pseudo-F statistic=7.31, P=0.001 comparing immune status) (left); PLS-DA (the 10-fold 1276 
cross validation Q2 value of 0.926) plot of metabolome (right) and (n) MUP and MUP;Cd8a-/-: PCoA plot 1277 
of microbiome data using unweighted UniFrac distances (PERMANOVA, pseudo-F statistic=4.61, 1278 
P=0.001 comparing immune status) (left); PLS-DA plot (the 10-fold cross validation Q2 value of 0.934) 1279 
plot of metabolome (right) illustrate the discordance stemming from these specific immune status 1280 
differences. (o) Bacterial Faith’s Phylogenetic Diversity metric (alpha diversity, box plot with min to max) 1281 
calculated with rarefaction at 4500 sequences/sample using Faith’s Phylogenetic Diversity metric (n=14, 1282 
8, 14, 25, 16, 6, 44, 34). (p) Heat map of abundant bacterial taxa by immune status, genetic background, 1283 
and diet. Trends in significantly differing taxa (ANCOM) by immune status include: increased 1284 
Gammaproteobacteria in Iga-/- with HFD and increased Ruminococcaceae in WT versus Iga-/- with HFD. 1285 
Mucispirillum schaedleri was elevated in Iga-/- for all groups except NC-fed MUP-uPA. (q) Discordance 1286 
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according to the immune status for the STAM model mice, left to right are shown: PCoA plot of 1287 
microbiome data using unweighted UniFrac distances; Principal Component Analysis (PCA) plot of 1288 
metabolome (the 10-fold cross validation Q2 value of the corresponding PLS DA analysis is 0.814). (r) 1289 
Box plot (min to max) of unweighted UniFrac distances comparing distances within Iga-/-, Pigr-/-, and 1290 
IgHEL/MD4 strains to distances between these strains (n=44, 40, 56) and WT or Cd8a-/- STAM mice 1291 
(n=16, 12, 12) for microbiome data. Two-sided T-test (Means±SEM; panel a,b,i,r) and Mann-Whitney test 1292 
(Median; panel c-h,j,o) were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not 1293 
significant. N-values for each group are shown either in individual panels or in legends for each group 1294 
from left to right accordingly. 1295 
Extended Data Figure 8 | IgA+ plasmocytes regulate tumor killing by CD8+ T cells. (a) Dih10 and 1296 
dihXY HCC cells were transfected with an inducible Ovalbumin (Ova) expression vector, and Ova 1297 
expression and presentation were confirmed by flow cytometry, using an antibody that recognizes the 1298 
SIINFEKL peptide on the MHCI molecule H-2Kb. (b-h) Ova-expressing dih cells or controls (dih-RFP) 1299 
were starved overnight (5% cell death), after which their medium was changed and B cells from WT, Iga-/-1300 
, Pdl1/2-/- or SW-HEL mice were added in the presence of TGFβ (5 ng/mL) and CTGF (3 ng/mL), for an 1301 
additional 24 hrs. Thereafter, the medium was replaced and CFSE-labeled OT-I T cells were added to the 1302 
cultures that either contained or did not contain the B cells described above. After 4-6 days, the co-culture 1303 
cells were analyzed by flow cytometry, while the secretory IgA were analyzed by ELISA (n=2-4 wells per 1304 
group per day). (a-j) Experiments were repeated with two different Ova-expressing HCC and one prostate 1305 
cancer cell lines. Shown are the representative flow cytometry histograms or plots depicting (b) OT-I 1306 
CD8+ T cell proliferation, (c) PD-L1 and SIINFEKL/H-2Kb expression on cancer cells, (d) PD-L1 1307 
expression on B cells, (e) cancer cell death. (f) Relative dih-Ova-RFP killing by OT-I CD8+ T cells in 1308 
presence or absence of indicated B cells. (g) Total secretory IgA and anti-OVA-IgA antibody amounts in 1309 
culture supernatants. (h) Percentages of OT-I CD8+ cells in each culture, as indicated. (i,j) TRC2-Ova-1310 
RFP cells or its control cell line (TRC2-RFP) were co-cultured with OT-I cells and splenic B cells (WT and 1311 
Il10-/-), as described for panels a-h. (i) Proliferation of OT-I cells was analyzed using CFSE (n=3, 7, 5, 4). 1312 
(j) The amounts of secretory IgA were analyzed using ELISA as indicated (n=3 per group). (k-o) Liver 1313 
cells from indicated 3m old mice were stained and analyzed by flow cytometry. Experiments were 1314 
repeated at least 2-3 times. Each dot represent one mouse. Shown are the percentage of CD8+ T cells 1315 
amongst CD45+ cells (n=6, 5, 3, 7, 4) (k), absolute CD8+ T cell number per gram of liver (n=3, 3, 7, 4) (l), 1316 
the percentage of CD8+CD44+Ki-67+ T cells with representative scatter plots (n=3-4 per group) (m,n) and 1317 
the representative scatter plots of Perforin and GrzB amongst CD8+CD44+Ki-67+ T cells (o). (p,q) Liver 1318 
cell suspensions from the indicated mice were stained as indicated and analyzed by flow cytometry to 1319 
determine the absolute CD8+ T cell number in both STAM-BL6 and STAM-FVB mice (n=8, 4, 5, 3, 5, 5, 6, 1320 
7) (p), the percentage of TEM cells using CD8, CD44, and CD62L (n=4, 4, 6, 9) (q). (r) Liver cells from 1321 
indicated 3, 6 and 11m old mice kept on HFD (n=4-10) were stained and analyzed by flow cytometry. 1322 
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Shown are the percentage of CD8+IFNγ+CD107a+ T cells. Detailed n-values are shown in Fig. 3e. (s-y) 1323 
Liver cell suspensions from the indicated mice were stained as indicated and analyzed by flow cytometry 1324 
to determine the percentage of Th17 cells using CD4 and IL-17a (n=4, 7, 9, 10, 4, 9, 11) (s), the 1325 
percentage of Treg cells using CD4 and Foxp3 (n=4, 3, 8, 11, 7, 13) (t), the percentage of Tfh-like cells 1326 
using CXCR5, PD1 and CD4 (3, 5, 6, 5) (u), the percentage of B220+CD19+ B cells (n=4, 7, 7, 4, 5, 3, 9, 1327 
3, 11) (v), absolute B220+CD19+ B cell number per gram liver (n=5, 7, 12, 27, 15, 7) (w), the percentage 1328 
of IgG+ cells (n=4, 3, 14, 11) (x) and CD138+ plasma cells (n=4, 7, 4, 7, 7, 8, 5, 8, 6, 6, 13, 27, 17) (y). 1329 
Two-sided T-test (Means±SEM; panel f-m) and Mann-Whitney test (Median; panel p-y) were used to 1330 
determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not significant. Mouse ages are indicated in 1331 
the graphs. N-values for each group in each panel are provided from left to right accordingly. 1332 
Extended Data Figure 9 | The response to PD-L1 blockade is dependent on CD8+ T cells and clonal 1333 
expansion of HCC-directed CD8+ T cells. MUP-uPA and MUP-uPA/Iga-/- mice were placed on HFD and 1334 
treated with αPD-L1, as described in Extended Data Fig. 2a. (a) At the end of the treatments, mouse 1335 
weights were measured (n=3, 2, 4, 3, 3, 7, 3, 7). (b) MUP-uPA mice treated with αPD-L1 were analyzed 1336 
for serum IgA by ELISA (n=10, 6). (c) Shown are the liver/body weight ratio of indicated strains kept on 1337 
HFD that received the indicated treatments and were of the indicated ages (6m, 11m) (n=4, 6, 9, 19, 6, 2, 1338 
4, 15, 11, 17, 3, 14, 7, 20). (d,e) Paraffin-embedded and frozen liver sections from HCC-bearing MUP-1339 
uPA mice were stained with ORO, H&E or SR, and analyzed (n=4-5). The experiments were repeated at 1340 
least 2 times. Low and high magnifications are shown in (e) to demonstrate the absence of tumor-1341 
invading immune cells in a mouse that failed to respond to αPD-L1 and their presence within a tumor of a 1342 
treatment responsive mouse. Non-responsiveness to αPD-L1 treatment correlates with a fibrotic tumor 1343 
stroma. Magnification bars; H&E: 250 μm; SR: 250 μm; ORO: 50 μm. (f) Response to PD-L1 blockade is 1344 
dependent on CD8+ T cells. HCC-bearing MUP-uPA/Cd8a-/- mice (n=3) were treated with αPD-L1 for 8 1345 
weeks and tumor multiplicity was determined. (g) A two-dimensional plot showing the frequency of the top 1346 
10 TCRα CDR3 sequences expressed by CD8+ T cells from spleens and livers of HCC-bearing MUP-uPA 1347 
mice. (h) CD8+ T cells were sorted from spleens and livers of NC- and HFD-fed WT mice (n=5 mice), their 1348 
RNA was extracted and TCR α (top) and β (bottom) chain CDR3 sequences were amplified and analyzed 1349 
by deep sequencing (10 samples). The panels show the clonality, the frequency of top 50 TCR α and β 1350 
sequences, and the % of productive unique TCRα and β sequences. (i-k) CD8+ T cells were sorted from 1351 
spleens and livers of HCC-bearing mice of the indicated strains and treatments (n=13 mice, 26 samples 1352 
as indicated) and their TCR α and β chain CDR3 sequence diversity was analyzed. Shown are the 1353 
clonality (i), the diversity (inverse Simpson’s index) (j) and % of productive unique TCRβ sequences in 1354 
indicated strains (k). Note that TCR sequencing data of WT, MUP-uPA and MUP-uPA/Iga-/- mice, are also 1355 
shown in Fig. 4g,h and Extended Data Fig. 9h. (l-n) Splenocytes from indicated mice treated +/- αPD-L1 1356 
were stimulated overnight with AFP, stained as indicated and analyzed by flow cytometry. Shown are % 1357 
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of IFNγ+CD107a+ cells (n=3, 3, 2, 5, 3, 2, 3, 4, 4) (l) and IFNγ+TNF+ cells (n=4, 3, 5, 4) (m) gated on CD8+ 1358 
T cells. (n) Shown are % IFNγ+TNF+ cells gated on CD4+ T cells (n=3, 3, 2, 4, 3, 2, 3, 6, 4). Two-sided T-1359 
test (panel a-d,f,h-n) and Mann-Whitney test (panel l) were used to determine significance. *P<0.05; 1360 
**P<0.01; ***P<0.001; n.s. not significant. N-values for each group in each panel are provided from left to 1361 
right accordingly. 1362 
Extended Data Figure 10 | Liver-IgA+ cells are oligoclonal and effects of HFD on control WT, Iga-/- 1363 
and Cd8a-/- mice. (a,b) B cells and plasmocytes (CD19+, CD138+, IgA+ cells) were sorted from spleens 1364 
(n=3) and livers (n=3) of HCC-bearing MUP-uPA mice and their μ (IgM) and α (IgA) locus genetic 1365 
diversity were determined by BCR sequencing. (c) Circulating ALT in HFD-fed WT, Iga-/- and Cd8a-/- mice 1366 
at 6m of age (n=5, 4, 8). (d,e,f) Paraffin-embedded and frozen liver sections from above mice were 1367 
stained with H&E, Oil red O (ORO) or Sirius Red (SR), as indicated. The data were validated at least 2 1368 
times. Magnification bars; H&E: 100 μm; SR: 100 μm; ORO: 50 μm. The SR (n=3, 4, 8) (d) and ORO 1369 
(n=3, 3, 6) (e) stained areas were quantitated. (g-i) Serum cholesterol (g) serum triglycerides (h) and liver 1370 
triglycerides (i) were measured (n=5, 4, 3). Two-sided T-test (panel a,d-i) and Mann-Whitney test (panel 1371 
c) were used to determine significance. *P<0.05; **P<0.01; ***P<0.001; n.s. not significant. N-values for 1372 
each group in each panel are provided from left to right accordingly. 1373 
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